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ABSTRACT 
 
  The accumulation of lipofuscins such as all-trans retinal dimer/cycloretinal in the 
retina may contribute to the progression of age-related macular degeneration (AMD). 
While the biosynthesis of cycloretinal is not fully understood, it has been shown that the 
milk protein β-lactoglobulin (BLG) can promote the cyclodimerization of all-trans retinal 
to cycloretinal both in vitro and in vivo. To further our understanding of this 
cyclodimerization, we have used site-directed mutagenesis of BLG as well as mass 
spectrometric analysis with substrate analogs to demonstrate that lysine residues play a key 
role in catalysis. It is shown that catalytic activity necessitates the presence of a physical 
binding site and cannot be mediated by a peptide chain. We also report that BLG is a 
promiscuous enzyme (a feature common to enzymes with a hydrophobic binding site and 
an active site lysine) that can catalyze the retroaldol cleavage of α, β unsaturated 
aldehydes. Retroaldolase activity was seen to be most effective on substrates with phenyl 
or napththyl side-chains. While the fluorescence images reported in this dissertation 
suggest that BLG may not be crossing into the retina to be the major protein responsible 
for cycloretinal biosynthesis, it might be possible that the blood-retina barrier becomes less 
coherent with age. These studies provide insight into the mechanism of the 
cyclodimerization process and provide a model system for biocatalysis and biosynthesis of 
cycloretinal in vivo.  In the long term, these studies may pave the way for drug 
development and inhibitor design as an early treatment regimen for AMD.  
. 
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NOMENCLATURE 
 
AMD Age-related macular degeneration 
BLG β-lactoglobulin 
ATR All-trans retinal 
RPE Retinal pigment epithelium 
MBP Maltose binding protein 
DTT Dithiothreitol 
SDS Sodium dodecyl sulfate 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Of the three most commonly diagnosed eye conditions (Table 1), Age-related macular 
degeneration is the most difficult to treat or detect.
(1)
 Ever since surgical treatment of 
cataracts became a routine procedure
(2)
, AMD has become the leading cause of blindness 
in people above the age of 50 in the United States of America.
(1, 3)
   
 
Table 1 Prevalence of AMD in the USA 
 
 
Eye disease 
 
Prevalence 
 
AMD 
 
1.6 million people above the age of 50 
 
Diabetic retinopathy 
 
5.3 million people above the age of 18 
 
Cataract 
 
20.5 million people above the age of 40 
 
 
 
Parts of this chapter are reprinted with permission from ‘Gowda, V., Foulke-Abel, 
J., Agbo, H., Bench, B. J., Chae, J., Russell, W. K., and Watanabe, C. M. H. (2017) 
Lipofuscin Formation Catalyzed by the Milk Protein β-Lactoglobulin: Lysine Residues in 
Cycloretinal Synthesis, Biochemistry 56, 5715-5719’. Copyright (2017) American 
Chemical Society 
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1.1 Epidemiology of AMD 
 
Studies into the prevalence of AMD in the United States of America by age and race have 
regularly found that Caucasians above the age of 80 are the highest at risk for AMD 
(Figure 1).
(3-5)
 This drastic increase in the prevalence of AMD in Caucasians vs other races 
could be due to dietary or lifestyle dissimilarities. Moreover, compared to Caucasians in 
the USA, AMD appears to be less common in Japanese people above the age of 50.
(5, 6)
 
The authors have hypothesized that this could be related to the higher consumption of an 
antioxidant by  
 
 
 
 
Figure 1 Prevalence of AMD in the USA by age and race 
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Japanese people. However, in the context of this dissertation, we should keep in mind that 
per capita milk consumption amongst Japanese is half the daily per capita milk 
consumption in the USA. 
(7)
 
 
1.2 Structure of the eye  
 
 
 
To better understand the types, cause and treatment of AMD, a basic understanding of the 
histopathology of the cells responsible for vision is required.   
The sclera is the outer layer of the eyeball (Figure 2). It is a protective layer and has little 
blood vessels.
(8)
  
Figure 2 Structure of the human eye 
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The choroid is the middle layer of the eyeball (Figure 2). The choroid has nearly all the 
blood vessels responsible for maintaining the retina 
 
The retina is the innermost layer of the eye that is responsible for vision.  Histological 
analysis of the retina (Figure 3) has shown that the retina can be divided into the following 
layers: 
 Just in front of the choroid is the retinal pigment epithelium (RPE)  
 Attached to the RPE are the photoreceptor cells (rods and cones). The area where 
the photoreceptor cells are present is called the outer nuclear layer 
  Other layers including outer plexiform layer, inner plexiform layer, ganglion layer, 
nerve fiber layer and inner limiting membrane that are transparent to light are found 
above the outer nuclear layer.
(8)
  
 
The macula is a collection of cells and specialized structures found in a disk under 250μm 
thick and less than 4mm in diameter near the center of the retina and is responsible for 
20/20 vision.
(1)
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The photoreceptor cells (rods and cones) contain the enzymes and structures necessary for  
phototransduction (the process by which light is converted into electrical signals that can 
be transmitted to the brain). Light dependent isomerization of rhodopsin activated 11-cis-
retinal to all-transretinal (ATR), a critical step in phototransduction occurs in the 
photoreceptor cells.
(9)
 Subsequently, the all-trans retinol produced at the end of 
phototransduction is converted back into 11-cis retinal by enzymes found in the RPE 
(Figure 4). 
(9)
 
 
 
Figure 3 Histopathological structure of the retina 
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Figure 4 The human vision cycle 
 
 
 
1.3 Etiology of AMD 
 
Any damage to the RPE, the photoreceptor cells or the blood vessels that supply blood to 
these layers (chroricapillaris) could lead to the loss of phototransduction activity.
(10)
 
Furthermore, the RPE cells, the photoreceptor cells and the choriocapillaris are physically 
and physiologically interconnected with a loss in any one of them resulting in the loss of 
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the other two. 
(11-14)
 If such degradation occurs in the macula, complete central vision is 
lost.
(1)
  
 
Accumulation of cellular by-products arising from the apoptosis or degradation of cellular 
material (including photoreceptor cells) lead to aggregates of a mixture of lipids, proteins  
and other cellular elements above the RPE called drusen.
(1, 15)
 The presence of noticeable 
drusen which does not necessarily affect vision is referred to as ‘dry AMD’ (Figure 5).  
 
The enlargement of drusen can result in a condition called geographic atrophy of the 
RPE.
(5)
 In such a scenario, the part of the RPE that undergoes atrophy loses its ability to 
phototransduce. If this affects the center of the macula (fovea), this could seriously impair 
Figure 5 Progression of AMD 
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vision. If instead of atrophy, there is choroidal neovascularization in the sub-RPE or sub-
retinal space, this could lead to severe vision loss and is known as ‘wet AMD’.(16) As 
shown (Figure 5), this only affects about 10% of the total number of patients with AMD 
but it accounts for nearly 90% of the severe visual loss seen in AMD patients.
(11)
  
 
1.4 Drusen and lipofuscin, a biochemical analysis 
 
The presence of drusen is often diagnosed as an early stage of AMD.
(15)
 In order to 
discover the biogenesis of drusen, it has been analyzed to identify the lipids and proteins 
that constitute this complex mixture. The drusen is a mixture of proteins, lipids, 
polysaccharides and glycosaminoglycans. Lipids like esterified cholesterol and 
phosphatidyl choline comprise about 40% of the drusen
(17)
 while more than one hundred 
proteins have been characterized in the drusen with clusterin, vitronectin and serum 
albumin being identified as the proteins present in the highest concentration.
(17, 18)
 While 
most of these characterized proteins are generally found in the RPE, it is noteworthy to 
mention that β-lactoglobulin (BLG), a bovine milk protein not biosynthesized in humans 
has also been identified in the drusen of patients affected with AMD.
(18)
   
 
1.4.1 A2E 
 
The degradation of photoreceptor cells (rods and cones) leads to the formation of 
lipofuscins (non-degradable fluorophores) in the RPE.
(19, 20)
 A majority of the characterized 
molecules in lipofuscin are derivatives of ATR.
(21)
 Of these compounds, the one most 
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studied is the bis-retinoid A2E. Not only does A2E damage cells via detergent action but it 
also undergoes photo-oxidation leading to the formation of DNA damaging epoxides.
(19)
  
A2E is predicted to be biosynthesized from 2 molecules of ATR and a molecule of 
phosphatidylethanolamine (PE) (Figure 6). The cyclization of PE activated ATR followed 
by oxidation and dephosphorylation is proposed to generate A2E.
(9, 22-24)
   
 
Figure 6  Proposed biosynthesis of retinoid-derived compounds found to accumulate in 
lipofuscins of the RPE.R groups in phosphatidylethanolamine designate the long alkyl 
chains. 
 
 10 
 
1.4.2 Cycloretinal 
 
A more recently characterized lipofuscin, ATR dimer or cycloretinal
(21-26)
 is very similar to 
A2E but lacks the enthanolamine fragment. While the cell-toxicity of cycloretinal is not 
well studied, it is reasonable to predict that photo-oxidation of cycloretinal could lead to 
cell damage in a manner similar to A2E.  
 
While cycloretinal could be generated chemically by activating ATR with an amine (like 
PE or proline) (Figure 7A),
(9, 25)
 such reactions have not been shown to progress in vitro at 
physiological pH.
(25, 27)
 An excess of base (triehylamine) is required for catalysis. 
Moreover, the identification that the R enantiomer of cycloretinal is preferably 
biosynthesized indicates the role of a stearic active site in this cyclodimerization.
(21, 26)
 It is 
therefore proposed that this cyclodimerization could be protein catalyzed (Figure 7B).    
 
1.5 Treatment of AMD 
 
Patients diagnosed with early stage AMD, dry AMD or geographic atrophy have no 
recourse to therapeutics and are only advised to get regular eye checks, quit smoking and 
take multi-vitamins so as to prevent wet AMD.
(28-30)
 Wet AMD is treated by injecting 
vascular endothelial growth factor (VEGF) inhibitors intravitreally at approximately six 
week intervals.
(1)
 Drugs like pegapatnib (nucleic acid)
(31)
 or bevacizumab (monoclonal 
antibody)
(32, 33)
 are currently being injected to prevent the growth of blood vessels in the 
retina, thereby delaying ‘wet’ AMD.  
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Figure 7  Proposed mechanism for cycloretinal formation mediated by A] 
phosphatidylethanoloamine B] proteinaceous lysine residues. 
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1.6 Beta-lactoglobulin and AMD 
 
Investigations into the synthesis and biosynthesis of cycloretinal
(21, 27, 34)
, a component of 
lipofuscin has led to the discovery that BLG can promote the cyclodimerization of ATR to 
cycloretinal both in vitro and in vivo.
(35, 36)
 The identification of BLG in the drusen of 
people affected with AMD
(18)
 and a study suggesting that milk consumption may lead to an 
increased likelihood of developing AMD
(37)
 has led to the proposal that BLG may have a 
role in the biosynthesis of the lipofuscin cycloretinal.  
 
BLG’s availability (it can easily be isolated from the whey fraction of milk)(38) has resulted 
in nearly 300 papers studying the biochemical and biophysical properties of the protein 
being published yearly since 1996.
(39-41)
While the role of BLG in milk processing and its 
role as an allergen
(42, 43)
 have been the target of extensive investigations in the dairy 
industry,
(44-46)
 its stability at low pH,
(47)
 the presence of a central hydrophobic cavity,
(48)
 the 
Tanford transition,
(49)
 its ability to bind lipids and retinol
(39)
 and its similarity to retinol 
binding protein
(50-52)
 have been of particular interest to protein chemists.  
Despite all these investigations, a role for this milk protein in humans, if any, has not been 
identified.  
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1.7 Structure of BLG 
 
1.7.1 Primary structure 
A phylogenetic tree generated by comparing the primary amino acid sequence of bovine 
beta-lactoglobulin with BLG found in other mammals (Figure 8) shows that the Bos taurus 
protein is most similar to the BLG found in sheep, goats, bison and water buffalo, all 
members of the family bovidae. Interestingly, the primary amino acid sequence for BLG 
found in Orcinus orca (killer whale) is more similar to that of bovine BLG as compared to 
the BLG found in Equus caballus (horse).
(53)
   
 
Figure 8 phylogenetic tree generated by comparing bovine BLG to BLG of other species 
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1.7.2 Tertiary structure 
The three-dimensional structure of BLG has been well characterized by X-ray 
crystallography 
(38, 39, 41, 54-81)
 and nuclear magnetic resonance (NMR) spectrometry.
(60, 82-85)
 
BLG is an 18.4 kDa protein which contains nine beta strands and a single three-turn alpha 
helix (Figure 9). Eight of the nine beta strands fold into a beta-barrel that contains the 
central hydrophobic cavity or calyx. The ninth beta strand is believed to form the dimer 
interface in the bovine protein.
(39)
   
 
A representative crystal structure of BLG bound to retinoic acid
(62)
 shows that the beta-
ionone ring of BLG is surrounded by hydrophobic residues: Leucine 32, Valine 43, 
Isoleucine 56, Phenyl alanine 105 and alanine 118. The polar carboxylate terminal of 
retinoic acid is surrounded by polar residues lysine 60, lysine 69 and glutamate 62 (Figure 
10). ATR is postulated to bind similarly in the hydrophobic cavity with the aldehyde group 
set up to form an imine bond with either lysine.  
Figure 9 Central hydrophobic cavity of BLG with retinoic acid bound 
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Various spectrometric studies support the theory that the EF loop of BLG located at the 
‘open’ end of the central calyx moves to ‘close’ the calyx when pH is lowered from 7.1 to 
6.2. This transition, referred to as the Tanford transition, suggests that the central calyx of 
the protein can only bind ligands at higher pH while being ‘closed’ at lower pH.(49, 83, 85, 86) 
Heteronuclear NMR studies indicate that the regions close to the entrance to the calyx (CD 
and EF loops) are locally unfolded at neutral pH which could correspond to the open 
state.
(83, 85)
 There is some crystallographic evidence for this transition.
(57, 59)
 The Kd of 
retinol with BLG at pH 2 or pH 7.5 is very similar suggesting that the tertiary structure of 
the protein is stable to acidic conditions.
(47)
  
 
1.7.3 Quaternary structure 
 
Bovine BLG is believed to exist as a dimer at neutral pH and as a monomer at lower pH.
(39, 
41)
 Comparison of crystal structures of goat,
(87, 88)
 sheep
(89, 90)
 and reindeer
(91)
 BLG to 
Figure 10 Cartoon of 3-dimensional structure of BLG 
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bovine BLG shows that all these proteins exist as dimers at native pH while horse BLG 
exists as a monomer.
(39)
  
 
1.8 Ligand binding of BLG 
 
Table 2  Selected ligand binding constants for bovine BLG 
 
 
Entry Ligand  Kd (M) Entry Ligand Kd (M) 
1 Lauric acid 7.0 x 10-7 5 Vitamin D2 4.91 x 10
-9 
2 Palmitate 1.0 x 10-7 6 Stearate 1.2 x 10-7 
3 Retinoic Acid 2.0 x 10-7 7 Cholesterol 3.49 x 10-8 
4 Retinol 1.5 x 10-7 8 β-Ionone 6.0 x 10-7 
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BLG has been crystallized with non-polar ligands including retinol,
(62)
 retinoic acid,
(62)
 
vitamin D,
(39, 67)
 dodecyl sulfate,
(74, 76)
 and various fatty acids (stearic acid,
(75)
 palmitic 
acid,
(58)
 oleic acid,
(75)
 myristic acid,
(73)
 lauric acid,
(56, 73, 74, 92)
 linoleic acid,
(75)
 decanoic 
acid
(55, 71)
) bound in its central hydrophobic cavity.  The native ligand of BLG has not been 
conclusively identified since BLG isolated from milk has not been crystallized with any 
ligands bound.  
 
The binding of ligands to BLG in solution has also been studied by various techniques 
(Table 2) with fluorescence titration being the most popular one.
(39)
 Since the initial 
discovery that retinol binds BLG, the energy transfer between a tryptophan residue of BLG 
(donor) and the ligand (acceptor) has been used to measure the dissociation constants for 
ligands
(47)
 including sodium dodecyl sulfate, palmitic acid, stearic acid, retinoic acid and 
retinol.
(93, 94)
 These studies have also reinforced the early observations that the Kd does not 
change when the pH is lowered from pH 7.5 to pH 2. The presence of a secondary binding 
site has been predicted with some crystal structures,
(67)
 molecular docking
(95)
 and FRET
(96)
 
studies finding evidence for multiple hydrophobic binding sites. An understanding of BLG 
catalyzed cyclodimerization may also help in the identification of a secondary binding site.  
 
1.9 BLG functional analysis 
 
BLG is classified as a lipocalin due to its eight stranded antiparallel beta barrel three- 
dimensional structure. Lipocalins are a family of proteins commonly associated with the 
transport of hydrophobic ligands.
(97)
 BLG’s structural similarity to retinol binding protein 
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(RBP) (Figure 11),another lipocalin, its ability to strongly bind retinol very similarly to 
RBP (Kd of both is in 10
-8
M range),
(52, 77, 97)
 its ability to solubilize hydrophobic ligands in 
aqueous solvents and its presence in human blood
(93, 98)
 has led to the ascription of a 
transport function for this protein.   
The discovery of receptors for BLG in the small intestine has supported the proposal
(98)
 
that BLG absorbs into the blood via the small intestine. Even though human blood has  
 
 
micro-molar concentrations of BLG in the human blood, very few studies have been 
undertaken to identify the fate of this protein. Using radioactive 
125
I- BLG, researchers 
were able to show that BLG which was intravenously introduced into blood is secreted into 
the milk of lactating mice.
(99)
 BLG has been found in the drusen of patients affected with 
Figure 11 Cartoon of 3-dimensional structure of RBP 
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AMD.
(18)
  Identifying the fate of blood BLG may help in identifying a transport function 
for this enigmatic milk protein.  
While the native function of BLG has remained elusive, it has been a target of various 
functionalization studies. Two of the important ones to discuss are drug delivery and 
catalysis.  
 
1.9.1 Applications of BLG in drug delivery 
 
Drug development is prone to failure with many potential drugs being rejected for non-
specificity or susceptibility to degradation.  To improve specificity and stability, drug 
delivery systems with the following properties are applied:
(100)
  
 Bio-compatibility: Any drug delivery agent has to be compatible with the living 
system that it is being applied to. Some of the most preferred targets for drug 
delivery development are therefore food or plant based compounds that are already 
regularly consumed or used in daily life and have been shown to be innocuous. 
Such materials prevent the necessity for costly clinical trials to prove their 
biocompatibility. Milk proteins are some of the most biocompatible 
compounds.
(100)
 Despite BLG being an allergen, a vast majority of humans 
consume milk containing BLG. Therefore, it has been an attractive target for drug 
delivery development.  
 Encapsulation properties: To prevent any active pharmaceutical or other ingredient 
from degrading, delivery agents are used to encapsulate the molecule. There are 
varying degrees of encapsulation. While protein binding the API in its cavity 
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prevents the material from degradation, this limits the choice of delivery agents to 
those that are naturally available and have the binding properties. Other techniques 
of encapsulation use the technique of self-assembly and co-assembly of protein 
nano-particles.
(100)
 Nano-particles of protein isolates (10 to 100nm in size) are 
prepared and then allowed to assemble into micelles, either by heat induced 
aggregation or desolvation.
(101)
 These micelles are then used to encapsulate target 
drug moelcules.  Nanoparticles of BLG have been prepared and shown to be 
structurally stable even at low pH.
(102)
 BLG-pectin nanoparticles have been 
introduced in acid beverages for delivery of vitamin D and other molecules.
(100)
  
 Bio-accessibility: Drug delivery targets have to be accessible to the tissues or cells 
that they intend to target. This is especially important in the case of oral drug 
delivery vehicles. Oral drug delivery vehicles should be resistant to pepsin 
digestion and tough acidic stomach environment. They should be easily absorbed in 
the intestines and selectively aggregate in the cells or tissue systems that they 
intend to target. Therefore, proteins like BLG that are stable at low pH
(47)
 and able 
to absorb into the blood through the small intestine
(98)
 are special targets for 
applications as drug delivery agents.  
 Bio-degradability: Any good drug delivery agent should be easily degraded and 
excreted from the body within a short period of time following the completion of 
its function. Proteins that can be easily degraded and excreted are generally the first 
targets for drug delivery application development.  
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Milk proteins other than BLG, mainly BSA are also well studied for drug delivery 
applications. For example, BSA nanoparticles for the delivery of the chemotherapeutic 
drug 5-fluorouracil have been developed.
(100)
 Human Serum albumin (HSA) has been 
shown to accumulate in solid tumours resulting in the development of a methotrexate-
albumin drug conjugate to selectively target tumour cells.
(103)
  
 
 
1.9.2 BLG’s catalytic applications 
 
For a long time, no catalytic function was attributed to BLG. While BLG’s native function 
might be as a carrier protein, like many other proteins,
(104, 105)
 BLG may moonlight as a 
catalyst promiscuous in its activity. Bovine serum albumin, another milk protein has been 
shown to catalyze Kemp elimination reactions, thiomichael addition reactions and aldol 
and knoevenagel condensations.
(106)
 
 
Even catalysts developed to perform specific functions, like catalytic antibody 38C2 which 
was raised to catalyze aldol reactions have been shown to catalyze reactions like the Kemp 
elimination. The enzyme was believed to use its hydrophobic pocket and the active site 
lysine to perform both aldol condensation and the Kemp elimination.
(105)
  
The de-novo designed and directionally evolved retro-aldolase, RA95.5-8 with activity 
approaching that of natural class I aldolases 
(107)
 is not just capable of retroaldol breakdown 
of hydrophobic molecules but is also able to catalyze Michael additions
(108)
 and 
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Knoevenagel condensations
(109)
 indicating that the presence of a hydrophobic cavity and 
active site lysine introduces promiscuous activity to these enzymes (Scheme 1.1).  
Similarly, the presence of a pair of lysines in BLG along with its hydrophobic calyx leads 
to the possibility that BLG can catalyze some of these reactions as well.  
 
Other work to introduce catalytic function to BLG includes the design of artificial 
metallocatalysts using BLG’s hydrophobic cavity (described in detail earlier) to bind 
diimine ligands carrying various fatty acid substituents and their d6-piano stool Ru/Rh 
complexes and then applying the complex to perform transfer hydrogenation of an 
activated aryl ketone in aqueous solvent, thereby affording (R)-enantiomer of the 
corresponding alcohol with ee up to 32%.
(110, 111)
 Further studies are underway to identify 
more functions for BLG and evolve its metalloenzymatic functionality.  
 
While enzymes currently do not find widespread use in the manufacture of chemicals, 
stricter environmental regulations and the cost of metal based catalysts might force the 
chemical manufacturing industry to direct themselves towards using enzymes in catalysis 
in which case the widely available milk proteins might be the cheapest starting point. With 
this in mind and the development of molecular biology techniques to manipulate BLG in 
cow and goat milk,
(112, 113)
 the exploration of BLG’s catalysis functions may be significant.  
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 1.10 Statement of purpose 
 
In these following chapters, we explain a novel strategy to express and purify recombinant 
BLG, and apply it to both probe the role of lysines in the cyclodimerization of ATR to 
cycloretinal as well as study the passage of BLG through the retina of BALB/c mice, all 
with the hope that these efforts may lead to a better understanding of the cause of AMD. 
We also demonstrate the retroaldolase activity of BLG and propose that BLG has the 
potential to be applied as a green catalyst in the chemical industry.  
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CHAPTER II  
EXPRESSION AND PURIFICATION OF BLG 
 
2.1 Introduction 
 
80 years’ investigation of BLG has shown that it can bind non-polar molecules,(39) is stable 
to pepsin digestion, can get absorbed into the blood through receptors in the small 
intestine,
(114)
 and is present at micro-molar concentrations in blood serum.
(98)
 Due to its 
presence in whey protein, and ease of isolation from milk, it is being applied as an 
encapsulation protein for nutraceutical delivery.
(100)
  
 
BLG has been shown to catalyze cyclodimerization of α,β-unsaturated aldehydes to their 
respective cyclodimers.
(35)
 To continue our investigations into BLG catalyzed 
cyclodimerization, to probe the role of lysines in cyclodimerization and to track the fate of 
serum BLG in animal models, we needed an efficient technique to express and purify 
BLG. While BLG has been expressed and purified in P. pistoris,
(115)
 the added complexity 
of glycosylation deterred us from following this route. Expression in mammalian cells has 
been reported, 
(116, 117)
 but this route was too slow to pursue. 
 
 
Parts of this chapter are reprinted with permission from ‘Gowda, V., Foulke-Abel, 
J., Agbo, H., Bench, B. J., Chae, J., Russell, W. K., and Watanabe, C. M. H. (2017) 
Lipofuscin Formation Catalyzed by the Milk Protein β-Lactoglobulin: Lysine Residues in 
Cycloretinal Synthesis, Biochemistry 56, 5715-5719’. Copyright (2017) American 
Chemical Society 
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While it would be ideal to express BLG in E.coli, this technique has resulted in BLG being 
expressed in inclusion bodies,
(116)
 likely due to the inability of the reducing environment of 
E.coli cytoplasm to support formation of the two disulfide bonds in BLG.
(118)
 Origami DE3 
(Novagen) cells are E.coli mutant cells with a cytoplasmic redox potential comparable to 
mammalian endoplasmic reticulum.
(119)
 By co-expressing disulfide bond isomerase (DsbC) 
with BLG in Origami DE3 (Novagen), soluble protein was isolated.
(119)
 Since the BLG was 
not tagged, the purification process included a precipitation step where the host cell protein 
was salted out by decreasing the pH. Around the same time New England Biolabs made 
commercially available an E.coli mutant that had a cytoplasmic redox potential comparable 
to mammalian endoplasmic reticulum and overexpressed DsbC (New England Biolabs 
catalog number C3029J). Other techniques to improve solubility of proteins that express in 
inclusion bodies include the use of solubility enhancing tags like E.coli maltose binding 
protein (MBP) which are known to promote proper folding and in some cases, even 
increase yield of their fusion partners.
(120)
  
 
In this chapter, we detail our laboratory’s success in expressing, purifying and 
characterizing soluble BLG (and its various mutants) using a cleavable, solubility 
enhancing E.coli maltose binding protein (MBP) tag.  
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2.2 Results and discussion 
 
2.2.1 Expression of His6 variant of BLG 
 
DsbC expressing mutant of BLG,  SHuffle® T7 Express (New England Biolabs) E.coli 
with a cytoplasmic redox potential similar to mammalian endoplasmic reticulum was 
expected to be capable of expressing BLG in the soluble form.  Our attempts to express 
BLG in this mutant strain of E.coli as a His6 variant failed to produce soluble protein. 
Other attempts by Dr. Jennifer Foulke-Abel to clone and express E.coli codon-optimized 
BLG variant B in popular pET or pQE vectors employing T7 or lac promoters also failed 
to produce soluble protein. 
 
2.2.2 Expression of maltose binding protein (MBP) tagged variant of BLG 
 
In our laboratory, the MBP-BLG fusion construct generated soluble fusion protein in 
excess of 100 mg/L under a tac promoter when induced with IPTG at 16°C. However, 
earlier attempts by Dr. Jennifer Foulke-Abel at cleaving MBP-BLG to obtain pure BLG 
using Factor Xa proved to be so inefficient a process that it was impractical to carry out at 
large scale. To explore different protein cleaving enzymes, a tobacco etch virus (TeV) 
cleavage site was strategically placed between the MBP and BLG proteins by Dr. Hillary 
Agbo.  
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His6 TeV protease was expressed and purified in our lab. While the TeV protease cleaved 
our fusion protein efficiently to give BLG (Figure 12), His6 BLG could not be separated 
from His6 TeV protease. A modified strategy to express tag-less BLG and then separate it 
from His6 TeV protease using ion-exchange chromatography yielded a mixture of uncut 
MBP-BLG fusion protein and cleaved BLG.   
 
Figure 12  His6 TeV protease cleavage of MBP-BLG fusion protein 
Figure 13 Screening of conditions for MBP-TeV protease catalyzed cleavage of 
fusion protein: 1] MBP-BLG fusion protein 2]MBP-Tev Protease 3] cleavage with 
5mM DTT; 4
0
C 4 days 4] cleavage with 20mM DTT; 4
0
C 4 days 5] Ladder  6] 
cleavage with 1mM DTT; 30
0
C o/n; 4
0
C 3days 7] cleavage with 5mM DTT; 30
0
C 
o/n; 4
0
C 3days 8] cleavage with 10mM DTT; 30
0
C o/n; 4
0
C 3days 
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Subsequently, we designed a strategy which would use MBP-tagged TeV protease instead 
of the His6 variant. Screening of cleavage efficiency indicated that the large MBP tag  
lowered the efficacy of the TeV protease. Evaluation of multiple cleavage conditions 
indicated that 30
o
C overnight was optimal for cleavage (Figure 13). However, this resulted 
in a significant loss of yield due to protein precipitation. BLG’s proven stability, and the  
need for a large amount of clean BLG, prompted us to cleave at 4
 
C over a week rather 
than 30
o
C overnight. Attempts to purify the protein subsequent to cleavage using Nickel 
affinity chromatography proved difficult since the uncut fusion protein co-eluted with the 
cleaved protein. Unsuccessful efforts to remove the uncut fusion protein by trapping it on 
an amylose resin column could have been due to maltose  tightly binding MBP.  
 
To overcome this problem, we designed two strategies:  
 1M Methyl α-D-glucopyranoside has been reported to elute MBP tagged proteins. 
While this was not as efficient as maltose and did reduce yield, it also dissociated 
readily from MBP enabling the tagged protein to bind amylose resin on a second 
pass (Figure 14). 
 The second strategy was to mix crude, clarified and filtered lysates of MBP-BLG 
and MBP-TeV protease together and incubate with 20mM DTT for a week. DTT, a 
known protease inhibitor does not inhibit TeV protease. Subsequent to cleavage, 
the mixture is purified by Nickel affinity chromatography to yield a mixture of 
uncut fusion protein and BLG.  The uncut fusion protein is then bound to an 
amylose resin column resulting in clean BLG flowing through. This technique 
yielded 7mg/L cell culture of clean, pure BLG. 
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Figure 14  Schematic diagram illustrating the BLG cleavage and purification process 
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2.2.3 Characterization 
 
The mass of the purified protein was analyzed by SDS-PAGE and ESI-MS. The mass 
detected by ESI-MS, 19404 Da matched the expected mass. Western blot analysis using 
anti-his antibody showed a single band corresponding to that of BLG (Figure 15).  
 
 
 
2.2.4 Mutagenesis 
 
A mutant of BLG where all the lysines were mutated to alanine (KA-BLG) was generated 
and overexpressed with a MBP tag. However, since the MBP tag could not be cleaved, 
possibly due to the inaccessibility of the TeV site, 8 glycines were added at the N-terminal 
of BLG to introduce a spacer between MBP and BLG. This construct was cloned, 
overexpressed and purified to obtain KA-BLG protein. Mutants of KA-BLG, A77K, 
Figure 15 Characterization of purified BLG by mass spectrometry and western blot 
analysis 
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A60K/A69K and A77K/A91K used in chapter 3 were also cloned, overexpressed and 
purified using the same strategy (Figure 16). KA-BLG and its mutants were observed to 
yield far less protein (0.5-2mg/L of cell culture) vs the wild-type variants (7mg/L of cell 
culture). The reduction in yield could be due to translation of mutants being affected in the 
absence of lysines.  
  
 
2.3 Significance 
 
The study of BLG has been limited by the lack of an efficient strategy for its expression 
and purification in E.coli. Our strategy to express and purify BLG using a cleavable, 
solubility enhancing E.coli maltose binding protein (MBP) tag has afforded us not only 
wild-type BLG but also its various mutants. Optimization of E.coli to improve the 
Figure 16 SDS-PAGE gels of purified KA-BLG; A6069K-BLG; A7791K-BLG and 
A77K-BLG 
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expression of disulfide bond containing proteins or the application of in vivo cleavage 
strategies may help in improving the yield of clean protein.  While the expression, 
purification and characterization of BLG and its mutants will allow us to explore the 
mechanism of BLG catalyzed cyclodimerization as well as track serum BLG in mice, those 
researchers interested in constructing chimeras of BLG or directionally evolving BLG to 
improve substrate specificity or kinetics now have access to a competent strategy to obtain 
catalytically active BLG mutants from E.coli.   
 
2.4 Experimental procedures 
 
2.4.1 Cloning of wt-BLG 
 
An E. coli codon-optimized version of Bos taurus BLG variant B (accession CAA88303) 
was synthesized and ligated to the TA cloning vector pQE-30UA (Qiagen, Valencia, CA) 
by GenScript (Piscataway, NJ) to generate the plasmid pQE30-BLG. To generate the 
maltose binding protein-BLG fusion construct, the BLG fragment was produced by PCR 
with primers BLG-BamHI-F and BLG-HindIII-R using pUC57-KA-BLG template with 1 
Taq MasterMix (M0483).  The N-terminal primer introduced a cysteine at the N-terminus 
of BLG. After agarose gel purification, digestion with BamHI and HindIII, the PCR 
fragment was ligated to the vector pMAL-c4X (New England Biolabs) using T4 DNA 
ligase at 16 °C to give the vector pMAL-BLG. Following transformation in E. coli 
DH10B, colonies were screened by PCR to identify positive clones and sequenced using 
pMALseqF and pMALseqR primers. 
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2.4.2 Cloning of Lys to Ala Mutant of BLG (KA-BLG) 
 
An E. coli codon-optimized version of Bos taurus BLG variant B with all lysine residues 
mutated to alanine was synthesized and ligated to the subcloning vector pUC57 by 
GenScript (Piscataway, NJ), giving plasmid pUC57-KA-BLG. To generate the maltose 
binding protein-BLG fusion construct, the KA-BLG fragment was produced by PCR with 
primers KA-BLG-BamHI and BLG-HindIII using pUC57-KA-BLG template with 1 Taq 
MasterMix (M0483).  The N-terminal primer introduced 8 glycines at the N-terminus to 
facilitate TeV cleavage by introducing a long gap between the TeV site and the BLG 
protein. After agarose gel purification, digestion with BamHI and HindIII, the PCR 
fragment was ligated to the vector pMAL-c4X (New England Biolabs) using T4 DNA 
ligase at 16 °C to give the vector pMAL-KA-BLG. Following transformation in E. coli 
DH10B, colonies were screened by PCR to identify positive clones and sequenced using 
pMALseqF and pMALseqR primers. 
 
2.4.3 Site Directed Mutagenesis of KA-BLG  
 
The QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa 
Clara, CA) was used to generate mutants A77K; A77&91K and A60&69K of KA-BLG.  
Primers (Table 3) were generated by the software provided on the Agilent website.  Each 
of the mutants was generated utilizing pUC57-KA-BLG as a template. Double mutants 
A7791K-BLG and A6069K-BLG were obtained by mutating A77K and A69K, 
respectively. The mutants were then cloned into pMALC4X (New England Biolabs) using 
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the primers KA-BLG-BamHI-F and BLG-HindIII. The resulting constructs were 
sequenced to confirm the correct DNA sequence and the TeV site between MBP and BLG.  
 
2.4.4 General conditions for overexpression and purification of BLG & its mutants  
 
2.4.4.1 Overexpression  
 
KA-BLG was transformed into BL21 DE3 cells by electroporation. The cells were then 
plated on LB-Agar plates containing ampicillin (100 µg/mL) and incubated overnight (~16 
h). An individual colony was then selected and grown overnight in 15 mL of LB medium 
containing 100 µg/mL ampicillin at 37 °C.  This starter culture was used to inoculate 1 L 
of LB Miller broth containing 0.2% glucose and 100 µg/mL ampicillin. The glucose helps 
to suppress endogenous amylases thus helping to increase protein expression.  The culture 
was shaken (225 rpm) at 37 °C to an optical density of 0.8 at λ 600 nm. This culture was 
then cooled to 16 °C and induced with 1 mM isopropyl β-thiogalactopyranoside for 20 h at 
16°C with a shaking frequency of 220 rpm. The cells were pelleted (7,000 rpm, 10 min), 
resuspended in 25 mL of column buffer (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 1 mM 
EDTA, 10% glycerol) and stored frozen at -80 °C. 
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Table 3 Primers used in this study 
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2.4.4.2 Purification  
 
The cell suspension was thawed at 4 °C.  β-Mercaptoethanol and phenylmethylsulfonyl 
fluoride was then added to the cell suspension (1 mM final concentration).  The cell 
suspension was lysed using a Branson Sonifier 450 fitted with a 5 mm microtip (6 15s 
pulses at 50% duty cycle, output setting 6, with 3 min cooling intervals). Care was taken to 
maintain the temperature of the cell suspension at 4 °C by carrying out the sonication in a 
cold room and keeping the solution on ice.  The debris was pelleted at 12,000 rpm for 90 
min. The resulting supernatant was diluted with column buffer (1:6 ratio) before applying 
to a 25 mL amylose resin (New England Biolabs) column (Kontes Flex-Column, 2.5 x 10 
cm) that was packed by gravity-flow and equilibrated with column buffer. The column was 
subsequently washed with 12 column volumes of column buffer and MBP-BLG eluted 
with column buffer containing 1 M α-methylglucopyranoside (AMG).  The purification 
process was carried out at 4 °C in a chromatography refrigerator. The resulting protein was 
confirmed by SDS-PAGE and the concentration of the protein determined by Bradford 
assay using commercial Bovine Serum Albumin (BSA) as a standard.  BSA was used as a 
standard since the size of BSA (66 kDa) is very similar to the size of the fusion protein.  
All mutants of BLG were expressed and purified as per the protocol detailed above.  
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2.4.5 Overexpression and Purification of MBP-TeV Protease  
 
2.4.5.1 Overexpression 
 
 The construct expressing an autolysis-resistant S219V mutant of MBP tagged TeV 
protease (addgene Plasmid #8835)
(121)
 was transformed into BL21 DE3 cells along with 
the tRNA accessory plasmid pRIL (from the BL21 CodonPlus strain, Stratagene) by 
electroporation. The cells were plated on LB-agar medium containing chloramphenicol (30 
µg/mL) and ampicillin (100 µg/mL) and incubated overnight. An individual colony was 
then selected and grown overnight in 15 mL of LB medium containing chloramphenicol 
(30µg/mL) and ampicillin (100 µg/mL) at 37 °C. This starter culture was used to inoculate 
1 L of LB Miller broth containing 0.2% glucose, chloramphenicol (30 µg/mL) and 
ampicillin (100 µg/mL). The glucose helps suppress endogenous amylases, thus helping 
increase protein expression.  The culture was shaken (225 rpm) at 37 °C to an optical 
density of 0.8 at λ 600 nm. This culture was then cooled to 30 °C and induced with 1 mM 
isopropyl β-thiogalactopyranoside for 4 h.  The cells were pelleted (7,000 rpm, 10 min), 
resuspended in 25 mL column buffer (50 mM Tris.HCl pH 7.5, 200 mM NaCl, 1 mM 
EDTA, 10% glycerol), and stored frozen at -80 °C. 
 
2.4.5.2 Purification  
 
The MBP-tagged TeV protease was purified using the protocol that was used to purify the 
BLG fusion protein. The presence of the protein was confirmed by SDS-PAGE analysis. 
 39 
 
The concentration was assessed by Bradford assay using commercial Bovine Serum 
Albumin (BSA) as a standard. 
 
2.4.6 Cleavage of the BLG Fusion Proteins by MBP tagged TeV Protease  
 
A schematic diagram illustrating the overall cleavage and protein purification process is 
shown in Figure 1, pg. S11.  To achieve cleavage, the purified KA-BLG protein and the 
MBP-TeV protease were dialyzed by centrifugal ultrafiltration (Amicon Ultra-15 
Centrifugal Filter Unit, Millipore, Billerica, MA) to a final concentration of 1 mg/mL in 
column buffer (50 mM Tris.HCl pH 7.5, 200 mM NaCl, 1 mM EDTA, 10% glycerol). The 
proteins were mixed and dithiothreitol (DTT) was added to give a final concentration of 20 
mM. The cleavage mixture was subsequently incubated at 4 °C for a 1 week period. 
During screening trials, cleavage conditions were varied by changing the concentration of 
DTT added after buffer transfer and by varying the incubation temperature and duration. 
Optimal conditions were found to be 20 mM DTT at 4 °C for 1 week. Cleavage was 
monitored by SDS-PAGE analysis.  Following incubation, the cleavage mixture was 
dialyzed by centrifugal ultrafiltration with loading buffer (50 mM Tris.HCl pH 7.5, 200 
mM NaCl, 5 mM imidazole, 10% glycerol). The protein was diluted to 50 mL and applied 
to a pre-equilibrated HisTrap FF 5 mL column (GE Healthcare Life Sciences, Piscataway, 
NJ) using a peristaltic pump at a rate of 0.2 ml/min. The column was washed with 200 mL 
of wash buffer (50 mM Tris.HCl, pH 7.5, 200 mM NaCl, 20mM imidazole, 10% glycerol) 
for 16 h. The column was subsequently washed with 25 mL of wash buffer containing 100 
mM of imidazole. Clean protein was eluted with elution buffer (50 mM Tris.HCl, pH 7.5, 
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200 mM NaCl, 250mM imidazole, 10% glycerol) and the resulting protein analyzed by 
SDS-PAGE.  The concentration of the protein determined by Bradford assay using BLG 
obtained from Davisco as a standard.  
 
2.4.7 Cleavage of wt-BLG Fusion Protein by MBP tagged TeV Protease without intial 
purification 
 
The cell suspension of wt-BLG and MBP tagged TeV Protease was thawed at 4 °C.  β-
Mercaptoethanol and phenylmethylsulfonyl fluoride was then added to the cell suspension 
(1 mM final concentration).  The cell suspension was lysed using a Branson Sonifier 450 
fitted with a 5 mm microtip (6 15s pulses at 50% duty cycle, output setting 6, with 3 min 
cooling intervals). Care was taken to maintain the temperature of the cell suspension at 4 
°C by carrying out the sonication in a cold room and keeping the solution on ice.  The 
debris was pelleted at 12,000 rpm for 90 min. The resulting supernatants were 
subsequently filtered by passing through a 0.2 μm filter. 25mL of wt-BLG supernatant and 
25mL of MBP-TeV protease supernatant was then mixed together. 1mL of 1M DTT was 
added to the resulting mixture to give a final concentration of 20mM DTT. This cleavage 
reaction was incubated at 4
0
C for 1 week. Subsequently, the mixture was dialyzed by 
centrifugal ultrafiltration (Amicon Ultra-15 Centrifugal Filter Unit, Millipore, Billerica, 
MA) with loading buffer (50 mM Tris.HCl pH 8.0, 200 mM NaCl, 5 mM imidazole, 10% 
glycerol). The protein was diluted to 50 mL and applied to a pre-equilibrated HisTrap FF 1 
mL column (GE Healthcare Life Sciences, Piscataway, NJ) using a peristaltic pump at a 
rate of 0.2 ml/min. The column was washed with 15 column volumes of wash buffer (50 
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mM Tris.HCl, pH 8.0, 200 mM NaCl, 20mM imidazole, 10% glycerol) for 16 h. Clean 
protein was eluted with elution buffer (50 mM Tris.HCl, pH 8.0, 200 mM NaCl, 250mM 
imidazole, 10% glycerol) and the resulting protein analyzed by SDS-PAGE.  The 
concentration of the protein determined by Bradford assay using BLG obtained from 
Davisco as a standard. 
 
2.4.8 Mass Spectrometric Analysis 
 
BLG solutions (0.4mg/mL) was dialyzed by centrifugal ultrafiltration (Amicon Ultra-
0.5mL 3kDa Centrifugal Filter Unit, Millipore, Billerica, MA) in 50mM ammonium 
acetate (pH=7.08) to a final concentration of 2mg/mL. This solution was prepped using 
zip-tip columns from Millipore. The tip was wet by withdrawing 20 μL acetonitrile twice. 
It was then equilibrated with 0.1% formic acid by pipetting out 20 μL of 0.1% formic acid 
four times. Sample was then bound to this tip by pipetting 20 μL of the sample ten times. 
To remove salt, the tip was then washed with 0.1% formic acid by pipetting 20 μL of the 
formic acid solution ten times. Finally, sample was eluted into a small, clean centrifuge 
tube by pipetting 15 μL of 7:10 (Acetonitrile/water) with 0.1% formic acid in and out of 
the loaded pipette tip.  
 
2.4.9 Western blot analysis 
 
After the protein was transferred to PVDF membraine (10V, 165 min), the membrane was 
incubated in blocking solution (3% bovine serum albumin solution in TBS buffer (50mM 
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NaCl, 10mM Tris-HCl pH 7.5)) for 60 minutes.  Subsequently, the membrane was washed 
twice with TBSTT buffer (500mM NaCl, 20mM Tris-HCl pH 7.5, 0.2% Triton X-100, 
0.05% Tween-20) for 20 minutes.  The membrane is then incubated with primary antibody 
(1μg his-tag monoclonal antibody in 10 mL blocking solution) for 10 minutes after which 
it was washed with 20mL TBSTT in two washes for a total of 20 minutes. The membrane 
was then washed with 15 mL TBS buffer for 10 minutes.  Afterwards, the membrane was 
incubated with secondary antibody (2μL goat anti-mouse AP conjugate in 10mL blocking 
solution) and then washed 4 times for 10 minutes each with 20mL TBSTT buffer.  To stain 
the membrane, AP detection reagent kit (Novagen 69264-3) was used. NBT-BCIP solution 
(750 μL 20X AP buffer, 60μL NBT, 60μL BCIP made up to 15mL with water) was added 
to the membrane and allowed to sit without shaking. Once color developed, the membrane 
is washed in water and air dried.  
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CHAPTER III  
LIPOFUSCIN FORMATION CATALYZED BY THE MILK PROTEIN 
ΒETA‑LACTOGLOBULIN: LYSINE RESIDUES IN CYCLORETINAL SYNTHESIS 
 
 3.1 Introduction 
 
Cycloretinal 3.2, also referred to as all-trans retinal dimer (Figure 17), has been isolated 
from the human eye and is one of several metabolites associated with age-related macular 
degeneration (AMD).(19, 22, 25, 26) AMD is the most common cause of blindness affecting 
adults over the age of 50.(122) In the early stages of the disease, the ‘dry’ form, this medical 
condition begins with the accumulation of yellow and white deposits in the macula (the 
central part of the retina of the eye).  These deposits contain lipofuscins, by-products of the 
visual cycle such as cycloretinal and A2E.(1, 19, 22, 25, 26) In the advanced stage of the disease, 
the ‘wet’ form’, blood vessel leakage results from vascularization of the macula leading to 
the loss of central vision.   
 
 
 
 
Parts of this chapter are reprinted with permission from ‘Gowda, V., Foulke-Abel, 
J., Agbo, H., Bench, B. J., Chae, J., Russell, W. K., and Watanabe, C. M. H. (2017) 
Lipofuscin Formation Catalyzed by the Milk Protein β-Lactoglobulin: Lysine Residues in 
Cycloretinal Synthesis, Biochemistry 56, 5715-5719’. Copyright (2017) American 
Chemical Society 
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Figure 18 Proposed mechanism for BLG catalyzed cyclodimerization 
Figure 17 BLG catalyzed cyclodimerization of retinal to cycloretinal 
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Bovine β-lactoglobulin (BLG) is a highly stable small protein (18.4 kDa) that constitutes 
between 12–15% of the protein content of milk. Although the protein has been extensively 
investigated,(41) its biological function has yet to be assigned. While BLG has been 
speculated as a transport protein, we have observed that the protein possesses moonlighting 
activity and is capable of promoting cyclodimerization of α, β-unsaturated terpenals to 
their respective cycloterpenals (Figure 17).  This includes the formation of cycloretinal 3.2, 
formed through condensation of all-trans retinal 3.1, in vitro and in vivo, as has been 
shown with a rabbit study.(35)  The cycloterpenals are a family of natural products of 
terpenoid biosynthetic origin with a central cyclohexadienal structural motif.(34, 123) It is 
proposed that BLG can catalyze the condensation of α, β-unsaturated aldehydes through 
one of two possible pathways: a stepwise Michael-like imine addition or a concerted Diels-
Alder-type reaction (Figure 18).  For the reaction to proceed, both mechanisms require the 
activation of aldehyde residues via the formation of a Schiff base with lysine residues of 
the protein. In this study, we evaluate the involvement of lysine residues via Schiff base 
formation in facilitating the reaction as well as the need of a physical binding pocket to 
promote catalysis.  
 
3.2 Results and discussion  
 
BLG contains 15 lysine residues within its primary sequence, 4 of which are contained 
within binding sites.  Analysis of the BLG crystal structure (PDB: 1GX9) reveals a central 
calyx, which has been reported to bind retinal 3.1. Lysine residues K60 & K69, which span 
4.8 Å, line the active site (Figure 19A).  A secondary binding site has been thought to exist 
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on the β-barrel exterior(67) with lysines K77 and K91 situated within ~12 Å of each other 
(based on crystal structure 1B8E, Figure 19B). In its native state, BLG exists as a dimer 
(Figure 19C). 
 
To evaluate the involvement of Schiff base formation and the role of lysine residues in 
cyclodimer formation, the reaction mixture was treated with sodium cyanoborohydride.  
This serves to trap the Schiff base intermediate (formed between the lysine and its 
aldehyde substrate and/or product) and reduces the imine bond to its corresponding amine.  
Since retinal and cycloretinal display light and temperature sensitivity, we employed the 
substrate analog citral to explore the BLG chemistry. Following reduction, the protein-
A B 
C 
Figure 19 BLG lysine residue pairs postulated to be involved in cycloterpenal catalysis: 
[A] Residues K60 and K69 on the β-barrel wall interior, [B] Residues K77 on the 
flexible loop and K91 on the β-barrel exterior, (1GX9), Lysine side chains are 
highlighted in red (1B8E), [C] Native dimer structure of BLG (1B8E) 
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bound complexes were fragmented by trypsin digest and the resulting short peptides 
analyzed by ESI-MS.  MS/MS analysis was performed, which enabled MASCOT-assisted 
prediction of peptide sequences.  Mining of fragment signatures revealed peptides 
containing residues K77 and K91 with citral substrate bound, and residue K91 with the 
product cyclocitral bound (Figure 20). Residues K77 and K91 are situated within 
reasonable proximity of one another, 12.8 Å (Figure 19B).  While K91 would be 
considered fairly immobile on the outer wall of the β-barrel, K77 resides on a flexible loop 
and could facilitate the reaction. However, time-course analysis revealed additional 
fragments of citral bound lysine residues, distributed in a randomized fashion, throughout 
the protein.  This is perhaps not surprising as the reaction is carried out with excess citral to 
achieve target residue saturation.  In a standard extraction of BLG incubated with citral, the 
aqueous phase retains a deep orange color (indicative of a citral-protein Schiff base) even 
after exposure to organic solvent.  While no additional lysine residues other than K91 
showed product bound, this raised some degree of ambiguity in the results. 
 
The generation and evaluation of BLG lysine mutants was the logical next step.  As the 
purified MBP-BLG fusion was shown to retain its activity to support cycloterpenal 
formation, site-directed mutagenesis was performed, generating lysine to alanine mutants 
at each of the fifteen positions.  However, as these mutants were not inactivating 
cycloterpenal formation as shown by HPLC, we modified the strategy whereby BLG was 
expressed as its MBP fusion and subsequently cleaved using a tobacco etch virus (TeV) 
cleavage site that was strategically placed between the MBP and BLG proteins. A C-
terminal His-tag on BLG was used to aid in the isolation of BLG. Circular dichroism (CD) 
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analysis of BLG showed no discernible change while monitoring the course of the 
reaction, which suggested no to minimal conformational change during the catalytic 
process and formation of cycloretinal (Figure 21).   
 
 
 
 
 
 
 
 
Figure 20 Mass spectrometric results obtained after trypsin digestion of BLG showing 
cyclocitral (homodimer product) bound to K91 
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Figure 22 HPLC analysis of cyclodimerization activity of BLG and mutants: A] wtBLG, 
KA-BLG B] A77K/A91K-BLG, A60K/A69K-BLG, A77K-BLG 
 
 
BLG and retinal over 1] 17hours 2] 41 hours 3] 72 hours 4] 90 hours 
Figure 21 CD analysis of BLG catalyzed cyclodimerization of all-trans retinal 
A] B] 
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To evaluate the role of lysines in cyclodimerization, we mutated each of the lysine residues 
of BLG to alanine (KA-BLG), to effectively “blank” the activity, with the idea of adding 
back specific lysine residues for evaluation.  The KA-BLG construct was cloned, 
overexpressed and shown to generate soluble protein.  We evaluated the ability of KA-
BLG to promote cycloretinal formation utilizing an HPLC assay (Figure 22A). The crude 
product was derivatized with 2, 4-dinitrophenylhydrazine (DNPH), analyzed by HPLC and 
quantified using a standard curve generated using a DNPH derivatized synthetic 
cycloretinal standard. 
 
With this assay, the KA-BLG mutant was shown to inactivate cyclodimerization (Figure 
22A), negating cycloretinal formation.  We, therefore, generated two sets of mutants.  We 
re-introduced the central calyx lysines K60 and K69 into KA-BLG giving A60K/A69K-
BLG and the secondary binding site lysines K77 and K91 giving A77K/A91K-BLG 
(Figure 22B).  Both sets of mutants restored activity, demonstrating that each pair of lysine 
residues is catalytically active. Total turnover number is defined as the ratio of moles of 
product generated divided by the moles of biocatalyst used in a reaction and is used to 
quantify activity of enzymes involved in non-native catalysis.
(124, 125)
 Comparison of total 
turnover number of both mutants (1.7 ± 0.1 μM per mM for A77K/A91K-BLG and 1.5 ± 
0.1 μM per mM A60K/A69K-BLG) showed that they were not as active as wild-type BLG 
(4.3 ± 0.2 μM per mM protein), which is consistent with the wild-type protein having more 
than one catalytic site.  To evaluate whether a single lysine residue is capable of catalyzing 
the reaction, we generated BLG with a single mutation, giving A77K-BLG (Figure 22B).  
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The single mutant was incapable of promoting the reaction, which is suggestive that two 
lysine residues are required for catalysis.    
 
 
To further corroborate these results, a 100-amino acid long truncated peptide mutant of 
DERA (deoxyribose 5-phosphate aldolase is a well-expressed E. coli protein), tDERA, was 
cloned, overexpressed and assayed for activity (Figure 23A). Despite having six lysines, 
tDERA was also shown to be catalytically inactive (Figure 23B), and demonstrates the 
importance of having a binding site to promote catalysis. SDS-treatment of BLG 
inactivates activity (Figure 24), which further reflects the importance of BLG’s tertiary 
structure and hydrophobic binding sites in the condensation process and formation of 
cycloretinal.   
. 
Figure 23 SDS-PAGE analysis [A] and HPLC analysis of cyclodimerization 
activity [B] of tDERA 
A] B] 
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Homology studies on BLG and a phylogenic analysis (Appendix figure 6 & 7, Page 119-
120) show that lysines 60, 69, 77 and 91 are highly conserved within members of the 
Bovidae family (cattle, bison, buffalo, sheeps and goats).  However, in comparison to other 
families that make up the order Cetartiodactyla including the Cevidae family (white-tailed 
deer and reindeer), the Delphinidae family (killer whales), the Physeteridae family 
(sperm whales) or the Balaenopteridae family (minke whales), lysine residues are shown 
to be mutated to glutamate.  Based on the literature, it is unclear as to what extent these 
animals suffer from AMD or whether the protein is present in the eye. While humans have 
no BLG homolog, BLG is transported to human serum from our diet
(98)
 and proteomic 
studies on both normal individuals and those with AMD have identified BLG as one of the 
major proteins in the eye.
(18)
 
Figure 24 1H-NMR analysis showing that SDS treated BLG does not catalyze 
cyclodimerization 
3.3 3.4 
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Figure 25 Evaluation of the mechanism with substrates analogs: condensation reaction with compounds 5 and 6 
3.5 
3.6 
3.8 
3.7 
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BLG has been shown to catalyze the cyclodimerization of a variety of aromatic substrates 
including cross condensation reactions in the formation of mixed dimers
(35)
.  In order to 
gain further insight into the mechanism of the BLG catalyzed cyclodimerization reaction, 
we designed an experiment to evaluate trapping of a reaction intermediate on the protein 
active site residue, utilizing compound 3.5 and brominated derivative 3.6 (Figure 25).  
Our rationale was that if cyclodimerization proceeded through a concerted Diels-Alder 
mechanism, deprotonation would result in the elimination of bromide resulting in the 
formation of a stable covalent amine bond between the protein’s active site lysine and 
reaction intermediate 3.7. Conversely, if the reaction proceeded through a stepwise 
mechanism, product 3.8 (Figure 25) would be formed.  Trypsin digestion and ESI-MS 
analysis of the control reaction (BLG incubated with 3.5), revealed product 3.9 (Figure 26) 
bound to lysine K91; a result which is consistent with our Schiff base trapping experiments 
with NaCNBH3. Mass spectrometric analysis of the reaction incubating both compounds 
3.5 and 3.6 with BLG did not reveal compound 3.7 bound to the protein. Moreover, 
extraction of the reaction with ethyl acetate and its subsequent analysis by H-NMR 
3.5 3.9 
Figure 26 Control reaction with compound 3.5 
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spectroscopy did not reveal the formation of compound 3.8.  However, compound 3.9 was 
also not isolated from the reaction mixture.  Hence, while reaction of 3.5 and 3.6 with BLG 
did not proceed as designed, compound 3.6 did appear to be serving as an inhibitor of the 
reaction.  
 
Trypsin digestion and subsequent peptide analysis by ESI-MS revealed lysines K91 and 
K60 bound to debrominated 3.6, shown as species 3.10, (Appendix Table 1, Page 118).  
Two other surface lysines (K135 & K8) also revealed labeling. These results are consistent 
with our mutagenesis studies and support the notion that inactivating single lysines of the 
lysine pair K60/K69 or K77/K91 eliminates cyclodimerization activity in BLG.  
Trypsin digestion and subsequent peptide analysis by ESI-MS revealed lysines K91 and 
K60 bound to debrominated 3.6, shown as species 3.9 (Figure 26).  Two other surface 
lysines (K135 & K8) also revealed labeling. These results are consistent with our 
mutagenesis studies and support the notion that inactivating single lysines of the lysine pair 
K60/K69 or K77/K91 eliminates cyclodimerization activity in BLG. 
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Figure 27 Mass spectrometric results obtained before trypsin digestion of BLG showing 
product bound to BLG 
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Figure 28 Mass spectrometric results obtained after trypsin digestion of product-bound  
BLG 
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Figure 29 Proposed mechanism for covalent labelling of BLG by 3.6 
 
 
3.3 Significance 
 
Understanding the mechanism of lipofuscin formation like cycloretinal, may contribute 
toward the development of therapies that control the progression of AMD. Proteomic 
studies on both normal individuals and those with AMD have identified BLG as one of the 
major proteins in the eye. 
(18)
 Humans have no BLG homolog, hence, the protein is derived 
from our diet.  Moreover, BLG has been shown to support cycloretinal formation in vivo, 
as revealed by a rabbit study. 
(35)
 It has been suggested that the biosynthesis of cycloretinal 
might involve proteinaceous acid-base catalysis and a chiral protein environment.
(25)
 Our 
findings here on the BLG promoted cyclodimerization of retinal to cycloretinal 
demonstrate the key role that Schiff base formation plays in catalysis, specifically that 
between the retinal aldehyde and lysine residues of the protein.  Moreover, the reaction 
3.6 
3.10 
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necessitates the involvement of two lysine residues (A60K/A69K or A77K/A91K), as 
opposed to one and a physical binding pocket.  A single lysine residue or a peptide chain 
does not support the reaction. BLG provides as a model system toward understanding how 
cycloretinal is formed and may lead to the identification of other endogenous proteins with 
similar properties that play a significant role in lipofuscin formation. 
 
3.4 Experimental procedures 
  
3.3.1 Instrumentation and General Methods 
 
NMR spectra were acquired on a Bruker Avance III 500 MHz spectrometer equipped with 
a 5 mm H-C-N cryoprobe (Bruker Corporation, Billerica, Massachusetts, USA) at 500 
MHz for 
1
H NMR and 125 MHz for 
13
C NMR in CDCl3.  Mass spectra (ESI) were 
obtained at the Laboratory for Biological Mass Spectrometry at the Department of 
Chemistry, Texas A&M University, with an API QStar Pulsar, MDS Sciex (Toronto, ON, 
Canada) Quadrupole-TOF hybrid spectrometer.  
 
3.3.2 General methods for trypsin digestion and mass spectrometric analysis 
 
Trypsin digest, liquid chromatography-mass spectrometry (LC-MS) and the associated 
data mining procedures were each carried out at the Laboratory for Biological Mass 
Spectrometry at Texas A&M University. Aliquots (75 μL) of each sample were desalted 
using a Micro Bio-Spin P30 column (BioRad, Hercules, CA).  Protein concentration was 
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adjusted to 0.1 mg/mL with (NH4)2HCO3 buffer and reduced with 5 mM dithiothreitol at 
60 °C for 1 h.  Subsequent protein alkylation was achieved using 20 mM iodoacetamide at 
room temperature for 10 min.  Protein samples were then digested with trypsin overnight 
(protein:enzyme ratio of 1:50) at 37 °C.  Separation and mass spectrometry were carried 
out on a NanoFrontier LC-MS (Hitachi High Technologies, Dallas, TX) equipped with a 
nanospray ESI source.  A 200 ng peptide sample was separated on a Vydac C18 capillary 
column (Grace Davison Discovery Sciences, 150 x 0.075 mm) at a flow rate of 200 nL/min 
under the following gradient routine employing water/acetonitrile and 0.1% formic acid in 
all conditions:  2% water/acetonitrile for 5 min, 2-10% over 0.1 min, 10-40% over 29.9 
min, 40-60% over 10 min, 60-98% over 5 min, 98% for 6 min, 98-2% over 1 min, 2% for 
13 min.  MASCOT-assisted predictions for modified lysine and carboamidomethyl groups 
on peptide fragments were used in manual examination of tandem MS/MS data.  Final 
spectra were produced by deconvolution to show the m/z +1 peaks and labeled to indicate 
the ion fragments resulting from b and y-type peptide cleavage. 
 
3.3.3 HPLC Analysis Conditions 
 
All samples in this study were analyzed using a Varian ProStar Liquid Chromatography 
system with a Luna 5 silica column (10 x 250 mm, 5 µm, 100 Å, Phenomenex) and a 
mobile phase gradient of 40% hexane in ethyl acetate to 20% hexane in ethyl acetate over 
30 min. with a 2 mL/min flow rate. A wavelength of 290 nm was used as it afforded the 
best signal to noise ratio for derivatized cycloretinal.  
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3.3.4 Cyclodimerization Assay Conditions  
 
Wild-type BLG or mutants of BLG (150 µM) was solubilized in 5 mL of PBS (10 mM 
phosphate buffer, 27 mM potassium chloride and 137 mM sodium chloride, pH 7.4) to 
which all-trans retinal (450 µM) was added. The reaction tube was covered with foil and 
incubated in a shaker (250 rpm) at 37 °C for 4 days
(35)
. The reaction was subsequently 
quenched by adding 5 mL of water and the solution extracted with ethyl acetate multiple 
times. The ethyl acetate fraction was dried over sodium sulfate and concentrated in vacuo. 
The resulting residue was stored at -80 °C until analysis. Prior to analysis by HPLC the 
organics were dissolved in 43.5 µL 0.07% HCl in methanol and the mixture derivatized 
with 16.5 µL of 2 mg/mL 2, 4-dinitrophenyl hydrazine.  The resulting mixture was 
analyzed by HPLC according to methods detailed on page S3.  The HPLC peak (Appendix 
Figure 1, Page 113) corresponding to cycloretinal was characterized by co-injection of 2,4-
dinitrophenyl hydrazine derivatized with synthetic cylocretinal. 
 
3.3.5 Cyclodimerization with SDS Denatured BLG 
 
Wild-type BLG (150 µM) was solubilized in 500 mL of PBS to which citral (450 µM) and 
50 g of SDS was added.  The mixture was shaken at 250 rpm for 4 days at 37 °C.  The 
BLG mixture was subsequently extracted with 2*500mL ethyl acetate and centrifuged to 
separate the organic layer. The organics were concentrated in vacuo and analyzed by NMR 
using CDCl3 as solvent.   
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3.3.6 Total Turnover Number (TTN) Analysis 
 
The amount of cycloretinal produced using wtBLG and its mutants was quantified using a 
standard curve generated with 2,4-DNP derivatized synthetic cycloretinal (Appendix 
Figure 2, Page 114). The amount of cycloretinal in micromoles was then divided by the 
number of millimoles of protein added to the reaction mixture to obtain TTN in terms of 
μM per mM of protein. 
 
3.3.7 Cloning of Truncated DERA 
 
The DERA gene was ordered from Genscript. The DERA gene was generated by 
amplifying the nucleotides coding for the first 100 amino acids of DERA using the primers 
mentioned in Table 1. The PCR product was purified and ligated into pET24b using the 
restriction enzymes NdeI and XhoI. 
 
3.3.8 Overexpression and purification of truncated DERA 
 
3.3.8.1 Overexpression  
 
The construct containing the truncated DERA was transformed into BL21 DE3 cells by 
electroporation and plated on LB-Agar plates containing kanamycin (50 µg/mL) and 
incubated overnight (~16 h). An individual colony was selected and grown overnight in 15 
mL LB media containing kanamycin (50 µg/mL) at 37 °C.  This starter culture was used to 
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inoculate 1 L LB Miller broth containing kanamycin (50 µg/mL). The culture was shaken 
(225 rpm) at 37 °C to an optical density at of 0.8 at λ 600 nm. The culture was cooled to 16 
°C and induced with 1 mM isopropyl β-thiogalactopyranoside for 20 h.  The cells were 
pelleted (7,000 rpm, 10 min), resuspended in 25 mL loading buffer (20 mM NaH2PO4, pH 
7.5, 200 mM NaCl, 5mM imidazole, 10% glycerol), and stored frozen at -80 °C.  
 
3.3.8.2 Purification 
 
 The cell suspension was thawed at 4 °C and β-mercaptoethanol and phenylmethylsulfonyl 
fluoride added to the cell suspension (1 mM final concentration). The cell suspension was 
lysed using a Branson Sonifier 450 fitted with a 5 mm microtip (6 15s pulses at 50% duty 
cycle, output setting 6, with 3 min cooling intervals). Care was taken to maintain the 
temperature of the cell suspension at 4 °C by carrying out the sonication in a cold room 
and keeping the solution on ice.  The cellular debris was pelleted at 12,000 rpm for 90 min. 
The resulting supernatant was diluted with loading buffer (20 mM NaH2PO4, pH 7.5, 200 
mM NaCl, 5 mM imidazole, 10% glycerol) in a 1:2 ratio, and applied to a pre-equilibrated 
HisTrap FF 5 mL column (GE Healthcare Life Sciences, Piscataway, NJ) with a peristaltic 
pump at a rate of 0.2 ml/min. The column was washed with 200 mL of wash buffer (20 
mM NaH2PO4, pH 7.5, 200 mM NaCl, 20 mM imidazole, 10% glycerol) for ~16 h, 
followed by a second wash with 25 mL of wash buffer containing 100 mM imidazole.  
Clean protein was eluted with elution buffer (20 mM NaH2PO4, pH 7.5, 200 mM NaCl, 
250 mM imidazole, 10% glycerol) and the protein subsequently analyzed by SDS-PAGE. 
The concentration of the protein was assessed by Bradford assay. Commercially available 
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BLG was used as a standard for Bradford assay as it was closer in size to the truncated 
DERA than Bovine Serum Albumin (BSA).  Subsequently, tDERA was assayed for 
cyclodimerization activity utiliizing the same conditions used to assay BLG catalyzed 
cyclodimerization. 
 
3.3.9 BLG-Citral Trapping Experiment with NaCNBH3  
 
Samples of BLG (1 mL, 1% w/v in PBS: 10 mM phosphate buffer, 2.7 mM potassium 
chloride and 137 mM sodium chloride, pH 7.4) were incubated with 4 molar equivalents of 
citral and 10 molar equivalents of NaCNBH3 at 37 °C for periods of 6, 24, 48, 72, and 96 
h.  A second set of BLG samples was set up in an identical fashion to which NaCNBH3 (10 
molar equivalents prepared in PBS) was added following each incubation period (6, 24, 48, 
72, and 96 h). After 2 h, the reaction mixture was dialyzed into 10 mM PBS, pH 7.4 using 
a millipore centrifugal filter (3 kDa). Two 75 μL aliquots of each time point were 
subsequently analyzed by trypsin digestion as detailed on page S3. 
 
3.3.10 BLG Reaction with 3-(naphthalene-2-yl)-but-2-enal  
 
Wild-type BLG was solubilized in 5 mL PBS (PBS: 10 mM phosphate buffer, 2.7 mM 
potassium chloride and 137 mM sodium chloride, pH 7.4) to give a 150 μM solution to 
which 3-(naphthalene-2-yl)-but-2-enal was added (450 µM). The reaction tube was 
covered in foil and incubated at 250 rpm for 4 days at 37 °C.  The sample (100 µL) was 
dialyzed with 400 μL of 50 mM ammonium acetate using a Millipore 3 kDa centrifugal 
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filter (10,000 rpm, 10 min).  The retentate was washed with 50 mM ammonium acetate and 
submitted for mass spectrometric and peptide analysis as detailed previously.  
 
~Note:  Due to the harsh conditions of trypsin digestion and analysis, the expected protein-
homodimer adduct will not be directly observed. However, if the homodimer is indeed 
bound to the protein, trypsin will not cleave at the labeled lysine site.  For example, we 
would expect to see the peptide ‘IDALNENKVLVLDTDYK’ in the reaction but not in the 
negative control. 
(126)
   
 
3.3.11 CD Analysis of BLG Promoted Cyclodimerization of All-Trans Retinal 
 
Wild-type BLG was solubilized in 5 mL PBS (PBS: 10 mM phosphate buffer, 2.7 mM 
potassium chloride and 137 mM sodium chloride, pH 7.4) to give a 150 μM solution to 
which all-trans retinal was added (450 µM). The reaction tube was covered in foil and 
shaken at 250 rpm for 4 days at 37 °C.  Aliquots (500µL) were taken daily and transferred 
to water using a Millipore 3 kDa centrifugal filter. The sample was then analyzed on a CD 
spectrometer (Chirascan) over the wavelength range of 200−400 nm for 5 min at 20 °C.  
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CHAPTER IV  
BIOCATALYSIS WITH THE MILK PROTEIN ΒETA-LACTOGLOBULIN: 
PROMOTING RETROALDOL CLEAVAGE OF CONJUGATED ALDEHYDES 
 
4.1 Introduction 
 
Enzymes that are versatile in their activity and substrate tolerance can be commercially 
applied to the production of chemicals and pharmaceuticals thereby increasing efficiency 
of manufacturing plants while reducing environmentally harmful waste.
(127)
 Natural 
enzymes, while highly proficient in the catalysis of their native substrates are not very 
versatile. Aldolases are a characteristic example of such enzymes with high activity 
towards their native polar substrates but very low tolerance towards hydrophobic ones.
(128, 
129)
 Various strategies including directed evolution,
(130)
 catalytic antibodies,
(131, 132)
 and 
computational design
(133)
 have been explored to design an aldolase with high activity 
towards non-polar molecules.  The de-novo design and directed evolution of a retro-
aldolase, RA95.5-8 with activity approaching that of natural class I aldolases has made the 
most progress toward this goal.
(107)
  Further investigations of RA95.5-8 indicate that this 
enzyme is not only promiscuous in substrate selectivity, but also in catalytic activity. 
Studies into the enzyme’s ability to catalyze Michael additions(108) and Knoevenagel 
condensations
(109)
 indicate that the minimum requirement for promiscuity in catalyzing C-
C bond generating reactions is an active site capable of binding hydrophobic molecules 
and an active site lysine to form iminium ions or enamines.   
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Bovine β-lactoglobulin (BLG) constitutes between 12–15% of the protein content of milk. 
Despite extensive investigations into its physical and biochemical properties for 
approximately 80 years, the protein’s function remains unassigned.(41)  Its size, stability, 
bioavailability and capacity to bind hydrophobic molecules in its central calyx have 
resulted in applications including encapsulation and nutraceutical delivery.
(134)
  The 
presence of an active site lysine capable of activating aldehydes by imine formation and a 
hydrophobic cavity led us to propose that BLG, like RA95.5-8, could also serve as an 
effective retroaldolase. Previously, we have shown that BLG can promote condensation of 
α, β-unsaturated aldehydes, to their respective cyclodimers through C-C bond formation.(35, 
135)
  For example, condensation of all-trans retinal 4.1 yields the formation of all-trans 
retinal dimer, cycloretinal 4.2 (Figure 30). 
 
 
Here, we report on the results of our investigations, which suggest that BLG is able to 
catalyze the retro-aldol breakdown of α, β-unsaturated aldehydes.  Exploration of the 
Figure 30 BLG catalyzed cyclodimerization of all-trans retinal to cycloretinal 
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substrate scope of BLG’s retroaldolase activity revealed that substrates with aromatic, non-
polar side chains are preferred to aliphatic or polar head groups.   
 
4.2 Results and discussion 
 
Synthesis of the α,β-unsaturated substrates was achieved by invoking a Horner-
Wadsworth-Emmons reaction to give the E-alkene ii, followed by DIBAL reduction of the 
nitrile, as shown for the formation of β-methyl naphthene aldehyde 4.5 (Figure 31A).(136)  
Due to the similarity between compound 4.5 and methodol, a compound used to study 
retroaldol reactions, we initially chose this compound to evaluate the cleavage products of 
the reaction.  
 
 
Figure 31Oxidative cleavage as mediated by BLG:  A] Synthesis of β-methyl naphthene 
aldehyde 4.5: i NaH, DCM; ii DIBAL-H, -60 °C; iii H2O;  B] BLG catalyzed oxidative 
cleavage of β-methyl naphthene aldehyde 4.5 
 
B] 
A] 
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Compound 4.5 was incubated with BLG in PBS buffer at 37 °C and the organics 
subsequently extracted with ethyl acetate.  Analysis by HPLC, revealed the formation of 
four peaks (Figure 32A). Each peak was collected and analyzed by NMR spectroscopy. 
 
 
 
Figure 32 Evaluation of BLG reaction by HPLC analysis: A] BLG reaction with compound 
4.5, B] BLG reaction with compound 4.13, C] acetonaphthone 4.3 synthetic standard 
 
 
The expected homodimer 4.6 was observed in peak a. Peak b was structurally 
characterized as acetonaphthone 4.3, which was also validated by comparison with 
acetonaphthone 4.3 standard (Figure 32C). Peak d was identified as starting material 4.5 
by H-NMR spectroscopy and Peak c was shown to be a compound closely related to the 
starting material; however, it wasn’t isolated in sufficient quantities to fully characterize it.  
a 
b 
c 
d e 
f 
g 
h 
A] B] C] 
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4.5 
4.5 
Figure 33 Control reaction showing that in the absence of protein, compound 3 does not 
non-enzymatically break down into acetonaphthone 
4.3 4.7 
4.5 
Figure 34 Proposed mechanism for BLG catalyzed retroaldol cleavage 
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A control reaction where 4.5 was incubated with PBS over 4 days resulted in the retrieval 
of only starting material (Figure 33). 
 
The scope of the reaction was evaluated with a series of α, β-unsaturated aldehyde 
substrates, Table 4.  The retro-aldol breakdown product for each was characterized by 
HPLC co-injection with synthetic standards and the total turnover number (TTN) for each 
substrate was evaluated as shown in Table 4.  BLG was shown to be most effective in the 
retroaldol cleavage of compounds with aromatic, phenyl 4.10 or naphthyl 4.5 side chains.  
Extending the side chain to that of a biphenyl- 4.11 or fluorene 4.12 groups resulted in a 3- 
to 10-fold reduction in retroaldolase activity, respectively.  Likewise, the more polar 
aromatic substrate, 2-methyl furanyl 4.9 moiety and the aliphatic substrate 4.8 showed very 
little to no retroaldolase activity.  This is thus suggestive that the retroaldolase activity 
favors that of a hydrophobic binding cavity that most effectively accommodates phenyl 
and naphthyl sidechains.  
 
The proposed route for cleavage of the α, β-unsaturated double bond of 4.5 to generate 
acetonaphthone 4.3 is depicted in Figure 34.  Hydrolysis of the imine activated double 
bond (via a lysine residue within the BLG binding pocket) initiates the process followed by 
a retro-aldol like cleavage of the C—C single bond.  The preference for aromatic groups 
over aliphatic side-chains is likely due to resonance stabilization of a transition state C-3 
carbocation during C-C bond cleavage.   
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Table 4 Evaluation of scope of the retroaldol reaction using a series of substrates 
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In light of this mechanism, we evaluated whether a cyclodimerization inhibitor, 3-
bromocinnamaldehyde 4.13 (Figure 35A),(53) could effect an enhancement in retro-aldol 
activity.  Brominated 4.13 has been previously shown to inactivate key lysine residues 
(Figure 29) as validated by trypsin digestion and ESI/MS analysis.(53)  
 
 
 
The cyclodimerization process necessitates the involvement of two BLG lysine residues(53) 
as opposed to one for the retroaldol cleavage.  Hence, inhibitor 4.13 is expected to have a 
more substantive effect on the dimerization reaction as opposed to that of the oxidative 
cleavage.   Compound 4.13 was synthesized from acetophenone 4.14 using the Vilsmeier-
Haack reaction according to Figure 35B.(137)  BLG was incubated with a 1:1.5 ratio of 4.5 
to 4.13 in PBS buffer at 37 °C. The reaction mixture was subsequently quenched and 
extracted with ethyl acetate. HPLC analysis showed 4 peaks (Figure 32B) that were 
3
O
BLG
+
Br
O
O
4
A
8
B
O
9
N
O
+
Br
O
10 8
PBr3, 0 °C
Figure 35 Effect of substrate analog 4.13 on retroaldol cleavage: [A] BLG catalyzed 
retroaldol cleavage of β-methyl naphthene aldehyde 3 in the presence of inhibitor 8; [B] 
Synthesis of substrate analog 4.13 
4.13 4.5 4.3 
4.14 4. 5 4.13 
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collected and characterized by H-NMR spectroscopy. Peak f was confirmed as 
acetonaphthone 4.3. Cyclodimer 4.6 was not observed indicating that treatment with 4.13 
eliminated cyclodimerization activity of BLG. While peak e eluted at about the same 
retention time as the homodimer 4.6, it was structurally characterized as 4.13. Peak h was 
confirmed as 4.5 and peak g was also not isolated in sufficient quantities for accurate 
characterization. 
 
The amount of acetonaphthone 4.3 formed in each experiment was quantified by HPLC 
analysis utilizing a standard curve (Appendix Figure 16, Page 129). Addition of 
cyclodimerization inhibitor 4.13 more than doubled the yield of acetonaphthone (0.45 
mg/L) compared to incubation of BLG with 4.5 alone, which yielded only 0.18 mg/L of the 
acetonaphthone cleavage product.  
 
Control experiments with 4.5 or 4.16 (Figure 36), which differ only by the presence of a 
bromo- or methyl-group at C-3, were carried out. Synthesis of 4.16 was achieved in the 
same manner as the synthesis of 4.13. ESI-MS analysis showed lysine labeling with 4.16 
while no labeling was observed with 4.5, which further substantiates that the bromo-group 
is critical for covalent labelling (Table 5).  
 
 
 
 
 75 
 
 
Figure 36 Brominated analog of compound 4.5 
 
 
 
 
Table 5 Labelling of BLG with brominated substrate analogs 
 
 Expected mass Observed mass 
BLG + 1 molecule of 
compound 4.13 
18407.16 
& 18492.759 
18407.1992 
& 18494.1992 
BLG + 2 molecules of 
compound 4.13 
18538.32 
&18623.919 
18538.900 
& 18628.5996 
BLG + 1 molecule of 
compound 4.16 
18458 
&18639 
18457.5000 
&18639.1992 
BLG + 2 molecules of 
compound 4.16 
18543.5996 
&18724.5996 
18545.3008 
& 18726.6992 
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4.3 Significance 
 
Although the TTN for BLG catalyzed retroaldol cleavage is much lower than de-novo 
designed proteins, the ready availability of BLG makes it a viable choice for biocatalytic 
investigations. Davisco Foods International alone produces over 10 million pounds of 
whey protein isolates annually. Here, we have shown that β-lactoglobulin has the 
capability to catalyze retro-aldol cleavage of the α, β-unsaturated aldehydes. Catalysis is 
proposed to proceed through initial hydrolysis of the α, β-unsaturated imine followed by a 
retro-aldol cleavage of the alcohol (Figure 34). Use of a cyclodimerization inhibitor, 
disables this competing reaction and enhances the retroaldol process. We have 
demonstrated that BLG is a versatile protein with the ability to not only promote 
condensation reactions but also, a retroaldol type cleavage reaction.  Evolution of these 
enzymes and/or further understanding of the mechanism of these reactions might lead to 
the development of BLG variants with higher catalytic efficiency and/or adaptable 
biocatalysts for commercial use.  
 
4.4 Experimental procedures 
 
4.4.1 Instrumentation and general methods 
 
All reactions were carried `out in flame-dried glassware unless otherwise noted. All non-
enzymatic reactions were magnetically stirred and monitored by thin layer chromatography 
(TLC), performed using glass-backed silica gel plates Analtech (#47011). Flash column 
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chromatography was performed using 60Å Silica Gel (Silacycle, 230-400 mesh) as a 
stationary phase.
 1
H & 
13
C NMR spectra for synthesized compounds were recorded on a 
Varian Inova 300 unless otherwise noted. 
1
H NMR chemical shifts are reported as  values 
in ppm relative to CDCl3 (7.26 ppm), coupling constants (J) are reported in Hertz (Hz).  
Compounds obtained from enzymatic reactions using substrate 3 were purified on a Varian 
ProStar chromatography system and analyzed by NMR spectrometry. NMR spectra were 
acquired on a Bruker Avance III 500 MHz spectrometer equipped with a 5 mm H-C-N 
cryoprobe (Bruker Corporation, Billerica, Massachusetts, USA) at 500 MHz for 
1
H NMR 
and 125 MHz for 
13
C NMR in CDCl3. Mass spectra (ESI) were obtained at the Laboratory 
for Biological Mass Spectrometry at the Department of Chemistry, Texas A&M 
University, with API QStar Pulsar, MDS Sciex (Toronto, ON, Canada) Quadrupole-TOF 
hybrid spectrometer. 
 
4.4.2 Materials 
 
Commercial solvents, reagents, Phosphate Buffer Saline (PBS) salts and acetonaphthone 
standards were used as received from Sigma-Aldrich. β-lactoglobulin was obtained from 
Davisco Foods International,Inc. (JE-003-6-922, La Sueur, MN, 93.6% BLG). 
 
4.4.3 General methods for trypsin digestion and mass spectrometric analysis 
 
Trypsin digest, liquid chromatography-mass spectrometry (LC-MS) and the associated 
data mining procedures were each carried out at the Laboratory for Biological Mass 
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Spectrometry at Texas A&M University. Aliquots (75 μL) of each sample were desalted 
using a Micro Bio-Spin P30 column (BioRad, Hercules, CA).  Protein concentration was 
adjusted to 0.1 mg/mL with (NH4)2HCO3 buffer and reduced with 5 mM dithiothreitol at 
60 °C for 1 h.  Subsequent protein alkylation was achieved using 20 mM iodoacetamide at 
room temperature for 10 min.  Protein samples were then digested with trypsin overnight 
(protein:enzyme ratio of 1:50) at 37 °C.  Separation and mass spectrometry were carried 
out on a NanoFrontier LC-MS (Hitachi High Technologies, Dallas, TX) equipped with a 
nanospray ESI source.   A 200 ng peptide sample was separated on a Vydac C18 capillary 
column (Grace Davison Discovery Sciences, 150 x 0.075 mm) at a flow rate of 200 nL/min 
under the following gradient routine employing water/acetonitrile and 0.1% formic acid in 
all conditions:  2% water/acetonitrile for 5 min, 2-10% over 0.1 min, 10-40% over 29.9 
min, 40-60% over 10 min, 60-98% over 5 min, 98% for 6 min, 98-2% over 1 min, 2% for 
13 min.  MASCOT-assisted predictions for modified lysine and carboamidomethyl groups 
on peptide fragments were used in manual examination of tandem MS/MS data.   
 
4.4.4 General methods for mass spectrometric analysis of BLG 
 
Protein samples were dialyzed into 50mM Ammonium acetate using millipore centrifugal 
filters. The samples were then analyzed by injecting 30 μL of each sample onto API QStar 
Pulsar, MDS Sciex (Toronto, ON, Canada) Quadrupole-TOF hybrid spectrometer. The 
obtained spectra was deconvoluted to obtain mass spectra as a function of intensity vs m/z.  
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4.4.5 HPLC analysis conditions 
 
All samples except the reaction with 4.5 were analyzed on Thermo Scientific™ 
UltiMate™ 3000 Rapid Separation HPLC system with a Prodigy 5μm ODS-2 150 Å, LC 
column 250 mm×4.6 mm(Phenomenex) and a mobile phase comprising water (with 0.1% 
formic acid) as inlet A and 75%:25% Methanol:Isopropanol (with 0.1% formic acid) as 
inlet B. The conditions used were: 0-1 min: 80%A; 1-23 min: gradient change to 0% A; 
23-33 min: maintain 0%A. A wavelength of 280 nm was used as it afforded the best signal 
to noise ratio. 
The reaction assay of compound 3 with BLG was analyzed using a Varian ProStar Liquid 
Chromatography system with a Luna 5 silica column (10 x 250 mm, 5 µm, 100 Å, 
Phenomenex) and a mobile phase gradient of 40% hexane in ethyl acetate to 20% hexane 
in ethyl acetate over 30 min. with a 2 mL/min flow rate. A wavelength of 280 nm was used 
as it afforded the best signal to noise ratio. 
 
4.4.6 Generic assay of BLG with α,β unsaturated aldehydes 
 
Assays with BLG were carried out according to procedures reported by Bench, et.al 
(35)
. 
BLG (150 µM) was added to 500 mL of PBS (10 mM phosphate buffer, 27 mM potassium 
chloride and 137 mM sodium chloride, pH 7.4) along with the α,β unsaturated aldehyde 
(450 µM). The 1L flask was covered in foil and shaken at 250 rpm, 37 °C in an incubator 
shaker for 4 days. The reaction was quenched by adding 500 mL of water and the solution 
extracted twice with 250 mL of ethyl acetate. The ethyl acetate fraction was dried over 
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sodium sulfate and concentrated in vacuo. The resulting compound was stored at -80 °C 
until further analysis. Prior to analysis by HPLC the organics were dissolved in 200 µL 
methanol.  
Assay with brominated compound 8 was repeated in the same manner except that 35.5 mg 
of compound 8 was added to the reaction mixture.   
 
4.4.7 Total Turnover Number (TTN) analysis 
 
The amount of ketone product produced using wtBLG was quantified using a standard 
curves generated with synthetic standards.  The amount of ketone product in micromoles 
was then divided by the number of millimoles of protein added to the reaction mixture to 
obtain TTN in terms of μM per mM of protein. 
 
4.4.8 Synthesis of α,β unsaturated aldehydes 
 
The α,β unsaturated aldehydes used in this study were synthesized according to previously 
reported procedures. They were characterized by comparing H-NMR to previously 
reported H-NMR data.
(27, 34)
  
 
4.4.8.1 Synthesis of (Z)-3-bromo-3-naphthylacrylaldehyde  
 
Compound 11 was synthesized similarly to the synthesis of compound 4.13. A solution of 
dimethylformamide (15 mmol, 3.0 equiv) in CHCl3 (10 ml) was cooled to 0 
o
C and PBr3 
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(13.5 mmol, 2.7 equiv) was added to the solution over 15 min. The reaction mixture was 
stirred at room temperature for 1 h. Acetonaphthone (5 mmol, 1 equiv.) was added to the 
solution and was allowed to stir overnight. The reaction mixture was then poured into ice 
water, neutralized with K2CO3 to a pH of 8 and extracted with Et2O (20 ml x 3). The 
organic phase was washed with brine, dried over MgSO4, and concentrated in vacuo. The 
compound was purified by flash column chromatography (1:30, EtOAc: hexanes). 
1
H 
NMR (300 MHz, CDCl3) δ 9.96 (d, 1H), 8.05 (s, 1H), 7.75-7.62(m, 4H), 7.51-7.46(m, 
2H), 6.73(d, 2H) 13C NMR (300 MHz, CDCl3) δ 193.6, 144.9, 134.6, 134.4, 132.7, 129.5, 
129.1, 128.6, 128.2, 127.7, 127.6, 127.2, 124.0 HRMS (ESI) calcd for C13H9BrO [M+Na] 
282.97346 and 284.97141, found 282.97040 and 284.96837 Since this compound has not 
been characterized before, we have also included DEPT, COSY, HMBC, HSQC and 
MS/MS analysis.  
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CHAPTER V  
APPLICATION OF CONFOCAL FLUORESCENCE MICROSCOPY TO TRACK THE 
PASSAGE OF BLOOD-BORNE BLG IN MOUSE EYE  
 
5.1 Introduction 
 
Bovine BLG is a lipocalin being investigated as a drug delivery system since it is resistant 
to pepsin digestion in the stomach, is absorbed into blood through special receptors in the 
small intestine
(35, 93, 98, 114)
 and has been shown to bind various non-polar ligands. The fate 
of the micromolar amounts of BLG observed in blood is not known. It has been shown that 
125
I labelled BLG introduced intravenously was secreted into the milk of lactating mice 
indicating that BLG can pass across the mammary epithelial cell barrier by exploiting the 
immunoglobulin transport pathway.
(99)
  
 
BLG’s similarity to RBP,(52) its ability to bind retinol(39) and its detection in the retina of 
people affected with AMD
(18)
 could mean that its native function is the transport of retinol 
to the retina.  BLG may also be transported across the blood-retina barrier in a manner 
similar to the transport of immunoglobulins.
(138)
 Once in the retina, it is possible that BLG 
moonlights as an enzyme that promotes the formation of cycloretinal, a component of 
lipofuscin.  
 
Confocal fluorescence microscopy allows for images of thin sections of a tissue to be 
obtained (without the need for mounting or processing the tissue in any way) which can be 
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assembled into a three-dimensional image of the sample.
(139)
 This technique can be applied 
to track the passage of a BLG-fluorescent molecule conjugate through the retina of a live 
mouse in real time to confirm whether BLG is actively transported across the blood-retina 
barrier.   
 
In this study, we overexpress a BLG mutant with an extra cysteine at its N-terminal, couple 
it to a fluorescent molecule functionalized with a maleimide group, characterize the BLG 
conjugate and use it to study the passage of blood borne BLG through the retina.   
 
5.2 Results and discussion 
 
5.2.1 Over-expression and purification of N-Cys-BLG mutant 
 
Since it has been shown that the only cysteine in BLG that is not involved in a disulfide 
bond is not accessible to solvent,
(64)
 a mutant of BLG with an extra N-terminal cysteine 
(N-Cys-BLG) was cloned, overexpressed and purified to afford clean protein characterized 
by SDS-PAGE and mass spectrometric analysis.  
 
5.2.2 Coupling N-Cys-BLG to N-hydroxyethylmaleimide  
 
Initial optimization of coupling conditions was carried out using a cheap alternative 
maleimide compound: N-hydroxyethylmaleimide (NEM). Screening studies helped 
discover that phosphate buffered saline (PBS) at pH=8.1 was the best buffer for the 
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maleimide coupling. The significant difference in coupling efficiency between pH 7.5 (0% 
by mass spectrometric analysis) and 8.1 (100% by mass spectrometric analysis) (Figure 
37) could be due to the slightly basic conditions helping deprotonate the cysteine side-
chain (pKa= ~8.3). The optimal concentration for DMSO, used to solubilize NEM was 
found to be 1% as any increase in DMSO concentration beyond that resulted in protein 
precipitation. Trypsin digestion and mass spectrometric analysis revealed that the two 
labelled cysteines were cysteines 4 (N-terminal cysteine inserted in the mutant, Figure 38) 
and 164 (C-terminal cysteine, Figure 39) were binding NEM.  The exposure of BLG to 
DTT during purification may have resulted in the reduction of the Cys70-Cys164 disulfide 
bond making cysteine 164 accessible to disulfide bond formation.   
 
 
Figure 37 When treated with NEM, the peak for N-Cys-BLG (mass=19404 a.m.u.) 
disappeared and a new peak corresponding to BLG+ 2 moles of NEM (mass= 19686 
a.m.u.) was seen 
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Figure 38 Cysteine-4 containing peptide labeled with NEM analyzed by trypsin digestion 
and mass spectrometry 
Figure 39 Trypsin digestion and peptide analysis showing cysteine-164 containing 
peptide labeled with NEM 
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5.2.3 Coupling N-Cys-BLG to ATTO532 
 
Similar conditions to that used for NEM was used to couple BLG to ATTO532. However, 
the BLG-ATTO532 conjugate could not be analyzed by mass spectrometry. This could be 
due to ATTO532 (whose complete structure was not provided by ATTOTec) affecting the 
ionization of the protein conjugate. While the digestion of N-Cys-BLG or BLG-NEM 
conjugate had unveiled all the expected peptide sequences, attempts to digest BLG-
ATTO532 conjugate using trypsin and subsequently analyze by mass spectrometry did not 
divulge the N-terminal and C-terminal sequences hinting that these peptides had been 
modified in a way that they could not be detected. 
 
To verify that the dye had indeed coupled covalently to the protein and was not just bound 
in the hydrophobic cavity, we purified the coupled protein by passing it through a Nickel 
affinity column. After binding the protein, it was washed until the flow-through did not 
have any absorbance at 532 nm. During elution fractions which showed absorbance at 
532nm were collected, treated with a protein denaturant, sodium dodecyl sulfate (SDS) and 
dialyzed with PBS for a week to allow for any non-covalently bound dye to dialyze out. 
Subsequently, the protein was concentrated and analyzed by SDS-PAGE. SDS and DTT 
treatment would denature the protein and any molecule bound in the hydrophobic cavity 
would be released into the surrounding solvent. However, SDS-PAGE analysis showed 
that the protein corresponding to the size of BLG was fluorescent suggesting that the dye 
may be covalently bound to BLG (Figure 40).   
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Figure 40 Characterization of BLG-ATTO532 conjugate by SDS-PAGE analysis  
 
 
The number of dye molecules bound to 1 molecule of BLG, calculated by estimating the 
concentration of BLG-ATTO532 conjugate (by amino acid analysis) and  the concentration 
of fluorescent molecule (from absorbance at 532nm), showed that 4 molecules of dye was 
bound to each molecule of BLG. This high number could be due to the cleavage of 
disulfide bonds by DTT resulting in the increased access of cysteines to coupling.  
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5.2.4 Imaging mouse retina 
 
The retina of BALB/c mice that were intravenously introduced with BLG-ATTO532 
conjugate, ATTO532 dye and saline was observed by fluorescence microscopy. While 
injection of saline showed only the autofluorescence of the retinal region (Figure 41A), 
injection of ATTO532 showed images (Figure 41B) resembling an angiogram of mouse 
retina (Figure 41C).
(140)
 The retina of mice injected BLG-ATTO532 conjugate was very 
similar to those injected just ATTO532 (Figure 42A). An hour after injection, there was no 
marked decrease in fluorescence (Figure 42B) but 48 hours after injection, no fluorescence 
was observed (Figure 42C). Repeated injections every 48 hours did not reveal any 
fluorescence beyond the blood vessels suggesting that there was no build-up of BLG-
ATTO532 conjugate in the retina. These results suggest that either the BLG-ATTO532 
conjugate is not transported across the blood-retina barrier in young mice or that the 
amounts being transported are not within our detection limits. Repeating the experiment 
with older mice may help us study the effect of age on coherence of the blood-retina 
barrier.  
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A] B] 
C] 
A] B] C] 
Figure 41 Confocal images of retina of mouse A] saline injection B] ATTO532 injection  
C] Angiogram of mouse retina 
Figure 42 Confocal fluorescence image of mouse retina after A] 15 minutes B] 1 
hour C] 48 hours 
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5.3 Significance 
 
In these studies, we have reported an effective method to couple BLG to a fluorescent 
molecule using cysteine-maleimide coupling, thus yielding a conjugate that can be applied 
to discover the fate of blood borne BLG. Our studies to trace BLG in mice suggested that 
the blood-retina barrier in young mice is impervious to BLG (within the detection limits of 
confocal fluorescence microscopy). Since BLG was detected in drusen of a 93 year old 
man affected with AMD, it is possible that our mouse model, using young mice, does not 
accurately simulate a potentially weaker blood-retina barrier of older humans. Future 
studies using older mice may help discover the origin of BLG in the drusen of patients 
affected with AMD and thereby lead to a better understanding of the cause of this 
debilitating eye disease.   
 
5.4 Experimental procedures 
 
5.4.1 Overexpression and purification of N-Cys-BLG 
 
N-Cys-BLG was overexpressed and purified as described in Chapter 2. 
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5.4.2 Coupling of BLG to N-hydroxyethylmaleimide 
 
The BLG purified from his-trap column was dialyzed by centrifugal ultrafiltration 
(Amicon Ultra-15 Centrifugal Filter Unit, Millipore, Billerica, MA) to a final 
concentration of 2mg/mL in phosphate buffered saline (PBS) (10 mM phosphate buffer, 
2.7 mM potassium chloride and 137 mM sodium chloride, pH 8.1 at 4
o
C). This BLG 
solution was divided into 100μL aliquots in clean autoclaved microcentrifuge tubes.  
5mg of N-hydroxyethylmaleimide was dissolved in 140 μL dimethyl sulphoxide 
biotechnology performance certified (DMSO) purchased from Sigma (D2438) in a clean, 
autoclaved microcentrifuge tube. 1μL of this solution was added to each of the 100μL 
aliquots of BLG. The resultant solution was gently mixed by pipetting with 100μL pipette. 
The reaction tubes were then covered with foil and incubated at 4
o
C for 20 hours.  
The solution was then dialyzed by centrifugal ultrafiltration (Amicon Ultra-0.5mL 3kDa 
Centrifugal Filter Unit, Millipore, Billerica, MA) in 50mM ammonium acetate (pH=7.08) 
to a final concentration of 2mg/mL. This sample was used for further mass spectrometric 
analysis.  
 
5.4.3 Trypsin digestion and mass spectrometric analysis of coupled BLG 
 
BLG solutions (0.4mg/mL) was dialyzed by centrifugal ultrafiltration (Amicon Ultra-
0.5mL 3kDa Centrifugal Filter Unit, Millipore, Billerica, MA) in 50mM ammonium 
acetate (pH=7.08) to a final concentration of 2mg/mL. This solution was prepped using 
zip-tip columns from Millipore. The tip was wet by withdrawing 20 μL acetonitrile twice. 
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It was then equilibrated with 0.1% formic acid by pipetting out 20 μL of 0.1% formic acid 
four times. Sample was then bound to this tip by pipetting 20 μL of the sample ten times. 
To remove salt, the tip was then washed with 0.1% formic acid by pipetting 20 μL of the 
formic acid solution ten times. Finally, sample was eluted into a small, clean centrifuge 
tube by pipetting 15 μL of 7:10 (Acetonitrile/water) with 0.1% formic acid in and out of 
the loaded pipette tip.  
Trypsin digest, liquid chromatography-mass spectrometry (LC-MS) and the associated 
data mining procedures were each carried out at the Laboratory for Biological Mass 
Spectrometry at Texas A&M University. Protein concentration was adjusted to 1 mg/mL 
with (NH4)2HCO3 buffer and reduced with 2 mM dithiothreitol at 25 °C for 1 h.  
Subsequent protein alkylation was achieved using 20 mM iodoacetamide at room 
temperature for 10 min.  Protein samples were then digested with trypsin overnight 
(protein:enzyme ratio of 1:50) at 37 °C.  Separation and mass spectrometry were carried 
out at the Laboratory for Biological Mass Spectrometry at the Department of chemistry, 
Texas A&M University, with API QStar Pulsar, MDS Sciex (Toronto, ON, Canada) 
Quadrupole-TOF hybrid spectrometer. Final spectra were produced by deconvolution to 
show the m/z +1 peaks and labeled to indicate the ion fragments resulting from b and y-
type peptide cleavage. 
 
5.4.4 Coupling of BLG to ATTO-532 
 
The BLG purified from his-trap column was dialyzed by centrifugal ultrafiltration 
(Amicon Ultra-15 Centrifugal Filter Unit, Millipore, Billerica, MA) to a final 
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concentration of 2mg/mL in phosphate buffered saline (PBS) (10 mM phosphate buffer, 
2.7 mM potassium chloride and 137 mM sodium chloride, pH 8.1 at 4
o
C). This BLG 
solution was divided into 100μL aliquots in clean autoclaved microcentrifuge tubes.  
1mg of ATTO-532 (ATTO-TEC GmbH, Germany) was dissolved in 20μL in phosphate 
buffered saline (PBS) (10 mM phosphate buffer, 2.7 mM potassium chloride and 137 mM 
sodium chloride, pH 8.1 at 4
o
C) in a clean, autoclaved microcentrifuge tube. 2μL of this 
solution was added to each of the 100μL aliquots of BLG. The resultant solution was 
gently mixed by pipetting with 100μL pipette. The reaction tubes were then covered with 
foil and incubated at 4
o
C for 20 hours. The ratio of protein to dye is 1:12.  
The solution was then dialyzed by centrifugal ultrafiltration (Amicon Ultra-0.5mL 3kDa 
Centrifugal Filter Unit, Millipore, Billerica, MA) in 50mM ammonium acetate (pH=7.08) 
to a final concentration of 2mg/mL. This sample was used for further mass spectrometric 
analysis and is referred to as BLG-ATTO532 conjugate.   
 
5.4.5 Purification and SDS-PAGE characterization of BLG coupled to ATTO532 
 
Coupled BLG was dialyzed by centrifugal ultrafiltration (Amicon Ultra-0.5mL 3kDa 
Centrifugal Filter Unit, Millipore, Billerica, MA) in loading buffer (50 mM Tris.HCl pH 
8.0, 200 mM NaCl, 5 mM imidazole, 10% glycerol). Fractions that absorbed at 532nm was 
pooled together and separated into 3 aliquots. One aliquot was treated with sodium dodecyl 
sulfate (SDS) and then dialyzed into phosphate buffered saline (PBS) (10 mM phosphate 
buffer, 2.7 mM potassium chloride and 137 mM sodium chloride, pH 8.1 at 4
o
C) over a 
week using dialysis bag. Once all the unreacted dye was removed, the protein was 
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concentrated and analyzed by SDS-PAGE. One half of the gel was stained with Coomassie 
blue stain and then compared against a ladder and the unstained gel.  
 
5.4.6 Determining concentration of BLG-ATTO532 conjugate by amino-acid analysis 
 
5.4.6.1 Instrumentation 
 
Hydrolysis of samples is performed in a PicoTag Workstation.  Amino acids are 
derivatized and separated on an Agilent 1260 liquid chromatograph with” 
Chemstation”  software that controls the LC and collects, analyzes and reports the 
data.  The G1367E autosampler performs pre-column derivatization and multiple sample 
handling. 
Derivatized amino acids are eluted from a narrow bore, (2.1 x 200 mm), (Hypersil AA-
ODS), 5 um reverse phase column purchased from Thermo Fisher (part # 30105-
202130).  Solvent A consists of a 20mM Na acetate buffer with 0.018% v/v triethylamine 
(Fluka 90338), 0.05mM EDTA, (Sigma E4884) and 0.3% tetrahydrofuran (Fluka 87363) 
adjusted to pH 7.2 with weak acetic acid.  Solvent B is a 20% 100 mM Na acetate buffer 
(pH 7.2) with 40% acetonitrile and 40% methanol.  The working gradient begins at 0 
minutes at 100% A at 0.45 ml/min and goes to 60% B over 17 minutes. 
Primary amino acids (tagged with OPA, Agilent Item # 5061-3335) are detected at 
338/390 nm by the Variable Wavelength (UV) detector (G1365D) and secondary amino 
acids (tagged with FMOC, Agilent Item #5061-3337 ) at 266/324 nm. 
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5.4.6.2 Assay description 
 
Protein samples (both unreacted BLG and BLG-ATTO532 conjugate) were aliquoted and 
mixed with internal standards (Norvaline, Sigma # N7502 for primary amino acids and 
Sarcosine, Sigma S7672 for secondary amino acids), dried in glass tubes (6 x 50 mm, 
Fisher PN 14-957AA) in a vacuum concentrator and subjected to vapor phase hydrolysis 
by 6N HCl (Thermo Sci # 24308) at 150ºC for 1.5 hours under argon atmosphere in the 
presence of phenol (2%, Sigma #P5566) which limits the halogenation of Tyrosine 
residues. The samples were subsequently reconstituted in 0.4 N Borate Buffer (Agilent # 
5061-3339) to bring the eventual pH to 10 for optimum derivatization and transferred to 
the Agilent G1367E autosampler for automated derivatization and loading. Standard amino 
acids eluted at discrete retention times in the working portion of the chromatogram and the 
ChemStation® software integrated the area under the peak of the amino acid and compared 
it to the area under the peak of its internal standard.  A line was generated by linear 
regression.  
Note:  Since hydrolysis is used, Asparagine and Glutamine are deamidated to their 
respective acids.  Results for these residues are reported as ASX and GLX to denote that 
these data contain the combined amounts from both the amide and the acid.  Acid 
hydrolysis also destroys Tryptophan. The assay is controlled by a known protein, a 
recombinant Human Serum Albumin (Pro-Spec-TanyTechnoGene #pro-595).  An aliquot 
from the same batch of HSA was run with every assay.  The data from these controls was 
used to calculate the inter-assay error of all the amino acids. 
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5.4.7 Determining concentration of ATTO-532 dye by Absorbance Spectroscopy  
 
The concentration of the ATTO-532 dye in the BLG-ATTO532 conjugate was determined 
by absorbance scanning in a Genesys 2 UV-Vis spectrophotometer (ThermoFisher 
Scientific, Waltham, MA) at 532nm with PBS serving as the absorbance blank and using 
the absorptivity co-efficient of 115000 M
-1
cm
-1
 provided by the vendor.  
 
5.4.8 Imaging mouse retina 
 
The following protocol (IACUC 2016-0168) was approved by the Texas A&M University 
Institutional Animal Care and Use Committee (IACUC).  The mice (BALB/c) were 
purchased from Charles River (USA). All adult mice were housed separately in standard 
cages in the Laboratory Animal Resources and Research (LARR) facility at Texas A&M 
University and maintained under standard conditions.  
The mice were initially anesthetized using ketamine:dexmitomodene 
(25mg/mL:0.25mg/mL) cocktail. Coupled BLG was dialyzed by centrifugal ultrafiltration 
(Amicon Ultra-0.5mL 3kDa Centrifugal Filter Unit, Millipore, Billerica, MA) into 
phosphate buffered saline (PBS) (10 mM phosphate buffer, 2.7 mM potassium chloride 
and 137 mM sodium chloride, pH 8.1 at 4
o
C)  to give a final protein concentration of 
2.5mg/mL. 200 microliter of this solution was intravenously introduced into the mice 
(n=2). Control injections with either saline or ATTO532 was also performed.   
Imaging analysis 
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The mouse retina was imaged on an inverted Nikon confocal scanning microscope. The 
imaging objective was a Nikon CFI 10X with a 0.30 NA. This objective is to be used in 
free space air, something that contributed to less optimal imaging quality, and will be 
discussed later. Three lasers were used as excitation sources. Their center wavelengths are 
488 nm, 543 nm, and 632 nm, respectively. The three emission filters used were a 540/30 
nm, a 590/50 nm, and a 650 nm longpass, with each corresponding to in order to their 
respective laser above. The dye used is most efficiently excited and detected using the 543 
nm laser and 590/50 nm filter combination.  
After anesthetization and injection of saline, ATTO532 dye or BLG-ATTO532 conjugate, 
the non-imaged mouse eye was covered using a gel lubricant. Likewise, the imaged eye 
was covered using an optically clear ultrasound gel with the same refractive index as water 
and a pupil dilating agent: Opcon-A (Bausch and Lomb, active pharmaceutical ingredient- 
naphazoline HCl and pheniramine maleate). The mouse eye was then placed on a cover 
slip and “coupled” to the surface via the ultrasound gel. This coupling made a homogenous 
medium between the coverslip and the mouse eye. The gel for both eyes was necessary 
because of the effects of anesthesia on the mouse. Prolonged exposure to air without the 
ability to blink will dry the cornea, cause damage, and make imaging more difficult. The 
reasons ultrasound gel was used in particular are that it is optically clear and possess a 
similar refractive index to water, i.e. tissue and the eye. The idea behind this is that the 
medium changes between the objective and the eye would reduce the effects of index 
mismatch, such as aberrations.  
After the mouse was correctly positioned, axial translation was used to find the interface 
between the cornea and glass. This was set as the zero positon for imaging. The stage 
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axially was translated roughly 3-4 mm into the eye. However, because the lens of the 
mouse eye itself has a focal length of about ~2.6 mm on average, the distance into the eye 
is not the same as the focal spot translation.
(141)
 Simple geometric optics suggest that the 
axial focal spot inside the eye would non-linearly relate to the axial translation of the stage. 
A simple simulation using raytracing software reveals this to be true. Note that this was 
assuming only the lens of the eye affected the light rays. Regardless, the effective focal 
distance was roughly 2 mm into the eye where an offset of 1 mm in either direction 
translates to ~.2 mm. These are rough estimations as a rigorous examination to determine 
the exact focal position within the eye was not done. The axial resolution of the 
microscope in optimal conditions is 11.2 µm. Aberrations caused by refractive index 
mismatch between the air objective and water imaging environment as well as additional 
mouse eye lens would likely degrade this. Z-stacks, or volumetric three dimensional 
stacks, were acquired at two different positions. One stack was taken at the focal plane of 
the retina and another at 1 mm superficial to this. The axial spacing of the Z-stack was set 
so that each image in the stack was 15 µm apart from one another and covered anywhere 
from 1 mm to 0.2 mm.  
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CHAPTER VI  
CONCLUSIONS 
 
Dry form of age-related macular degeneration, a neurodegenerative disease proposed to 
affect five million people by 2050 is characterized by the deposition of drusen and 
lipofuscins in the retina. The biosynthesis of lipofuscin is poorly understood.  
Bovine BLG is an enigmatic protein whose native function, if any, has been hard to 
unravel. Its similarity to RBP, its detection in the drusen of patients affected with AMD 
and its ability to cyclodimerize ATR to cycloretinal both in vitro and in vivo leads to the 
belief that this protein may be one of the proteins responsible for the biosynthesis of the 
lipofuscin cycloretinal. Our results lead us to believe that a hydrophobic cavity and two 
lysines relatively proximal to each other are necessary for the cyclodimerization of retinal 
to cycloretinal. While mutagenesis studies support the initial proposal that this catalysis 
happens in the central hydrophobic cavity of BLG, mass spectrometric and other 
mutagenesis studies support the theory that a secondary binding site of BLG with lysines 
77 and 91 may also be involved. Further studies utilizing BLG from other animals that 
may not contain secondary binding sites could lead to better understanding of this 
cyclodimerization mechanism.   
 
During these studies, we discovered that BLG can catalyze the retro-aldol cleavage of α, β 
unsaturated aldehydes on hydrophobic substrates. Retroaldolase activity, only the second 
enzymatic activity discovered for BLG, was seen to be most effective on substrates with 
phenyl or naphthyl side-chains.  Retroaldolase activity of BLG, when combined with an 
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efficient purification technique for BLG reported in this dissertation could lead to the 
development of a cheap, commercial catalyst. 
 
While our results also suggest that the blood-retina barrier in mice is not permeable to 
BLG-ATTO532 dye conjugate, it could be possible that a potentially weak blood-retina 
barrier in older patients may be permeable to this protein. Computational analysis of the 
one hundred and thirty other proteins found in the drusen may also discover that some of 
these have two proximal lysines along with a hydrophobic cavity and thus be capable of 
cyclodimerizing ATR to cycloretinal.   
  
 
Figure 43 Various factors could potentially contribute to the progression of AMD 
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Therapeutics to prevent drusen formation will need to include not only a cocktail of drugs 
that can inhibit lipofuscin formation and strengthen the blood-retina barrier but also gene 
editing agents to negotiate the genetic causes of AMD. Discovering enzymes that break-
down lipofuscins into easily execrable by-products might be a preferable alternative 
therapy. Delivering these enzymes through means other than injections to the eye would 
further help alleviate the discomfort that people with AMD would need to go through. 
Better healthcare which has nearly doubled life expectancy in less than a hundred years 
from less than 50 to more than 80 years has also led to the increased prevalence of age-
related diseases. Protein mediated biosynthesis of the lipofuscin cycloretinal is probably 
only one musician in a whole orchestra of factors (from dietary to genetic) involved in the 
development of AMD, a neurodegenerative disease. While dietary intake of milk does lead 
to increased chance of developing AMD
(37)
,  our experiments and a survey of literature 
have not revealed any conclusive evidence for a  direct correlation between dietary intake 
of BLG and AMD progression. However, our studies into BLG mediated catalysis reported 
in this dissertation have provided insight on the role of lysines in the biosynthesis of 
cycloretinal in vivo.  
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APPENDIX 
 
 
 
 
 
 
Figure A 1 Representative Co-injection of wt-BLG reaction with synthetic cycloretinal:  See S7 for details on reaction 
conditions 
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Figure A 2 Standard curve generated by analyzing different amounts of cycloretinal: synthetic cycloretinal was 
derivatized with 2,4-dinitrophenylhydrazine 
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LYSINE 77 
Figure A 3 Mass spectrometric results obtained after trypsin digestion of BLG showing citral bound to K77 
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LYSINE 91 
Figure A 4 Mass spectrometric results obtained after trypsin digestion of BLG showing citral bound to K91 
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Figure A 5 MS/MS results obtained after trypsin digestion of 3.9-bound BLG 
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Table A 1 Comparison of the Peptides Obtained from BLG Incubated with Compound 6 to Control BLG 
 
Labelled lysine Sequence
a
 Modifications Cha
rge 
MH+ [Da] ΔM 
[ppm] 
RT 
[min] 
Missed 
Cleavag
es 
Lysine 91+ 6 
IDALNEnkVLVLD
TDYK 
K8(VGTAMU) 3 2094.07560 1.69 34.41  1 
Lysine 91 control IDALNEnKVLVLD
TDYK 
No modification 2 1964.01897 -1.72 25.77  1 
Lysine 60+ 6 VYVEELkPTPEGD
LEILLQK 
K7(VGTAMU) 3 2443.30313 -2.24 38.85  1 
Lysine 60 control VYVEELKPTPEGD
LEILLqK 
No modification 4 2314.25258 4.17 30.95  1 
Lysine 135 + 6 TPEVDDEALEKFD
kALK 
K14(VGTAMU) 3 2078.02585 -7.18 26.03  2 
Lysine 135 control TPEVDDEALEKFD
KALK 
No modification 2 1947.98454 -3.35 19.56  2 
Lysine 8 or 14 (peptide 1-
40) 
LIVTQTMkGLDIQ
KVAGTWYSLAM
AASDISLLDAQSA
PLR 
K8(VGTAMU) 4 4406.31557 -1.43 41.83  2 
Control peptides 1-14 VAGTWYSLAMA
ASDISLLDAQSAP
LR 
No modification 3 2707.36777 -3.08 48.87  0 
Control peptide 15-40 LIVTQTMKGLDIQ
K 
No modification 3 1587.90580 -5.12 23.26  1 
                   a
Peptides obtained by digesting the proteins with trypsin were subjected to mass spectrometric analysis 
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Figure A 6 BLAST analysis showing conservation of lysines 60, 69, 77 and 91 among closely related species 
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Figure A 7 BLAST analysis showing conservation of lysines 60, 69 and 91 among distantly related species 
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Figure A 8 HPLC analysis of BLG assay with compound 4.9 
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Figure A 9 Analysis of synthetic ketone product of 4.9 to generate standard curve 
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Figure A 10 HPLC analysis of BLG assay with compound 4.10 
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Figure A 11 Analysis of synthetic ketone product of 4.10 to generate standard curve 
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Figure A 12 HPLC analysis of BLG assay with compound 4.11 
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Figure A 13 Analysis of synthetic ketone product of 4.11 to generate standard curve 
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Figure A 14 HPLC analysis of BLG assay with compound 4.12 
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Figure A 15 Analysis of synthetic ketone product of 4.12 to generate standard curve 
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Figure A 16 Analysis of synthetic ketone product of 4.5 to generate standard curve 
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Observed mass for BLG wild type: 18277 & 18362.5996 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 Expected 
mass 
Observed 
mass 
BLG + 1 
molecule of 
compound 8  
18407.16 
&18492.759 
18407.1992 
&18494.1992 
BLG + 2 
molecules 
of 
compound 8 
18538.32 
&18623.919 
18538.900& 
18628.5996 
BLG 
The other major peaks observed are 
peaks corresponding to the loss of a 
water molecule from the labelled 
peaks. This could be due to the 
formation of an imine bond between 
the aldehyde and lysine residue in the 
protein active site. Variation in 
number of protonation state of the 
lysine residues could lead to a 
variation of 2-3 amu.  
Figure A 17 Mass  spectrometric analysis showing BLG covalently 
bound to compound 4.13 
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                    Observed mass for BLG wild-type: 18277 & 18362.5996
      
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 Expected mass Observed mass 
BLG + 1 
molecule of 
compound 
11  
18458 &18639 18457.5000 
&18639.1992 
BLG + 2 
molecules 
of 
compound 
11 
18543.5996 
&18724.5996 
18545.3008& 
18726.6992 
On treatment with compound 11, BLG shows 
an increase in mass corresponding to the mass 
of debrominated compound 11. However, when 
BLG was treated with compound 3, no such 
increase in mass was observed. This provides 
support that the bromo substituent is responsible 
for the labelling of BLG by 11. 
BLG treated 
with  
Figure A 18 Mass spectrometric analysis showing BLG covalently bound to compound 4.16 
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Figure A 19 Characterization of compound 4.16 by 1H-NMR spectroscopy 
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Figure A  20 Characterization of compound 4.16 by 13C-NMR spectroscopy 
 
 
 144 
 
 
 
Figure A 21 Characterization of compound 4.16 by mass spectrometry 
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Figure A 22 Characterization of compound 4.16 by MS/MS spectrometry 
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Figure A 23 Characterization of compound 4.16 by DEPT 90 
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Figure A 24 Characterization of compound 4.16 by DEPT 135 
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Figure A 25 H, H-COSY of compound 4.16 
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Figure A 26 HMBC of compound 4.16 
 
 
 
 
 150 
 
 
 
Figure A 27 HSQC of compound 4.16 
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Homodimer standard was synthesized according to procedures previously reported by Bench, et. al 
(123)
. 
 
Synthetic standard 
Figure A 28 Characterization of peak ‘a’ by 1H-NMR spectroscopy 
Peak a 
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Synthetic standard 
Peak d 
Figure A 29 Characterization of peak‘d’ by 1H-NMR spectroscopy 
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Peak e 
Synthetic standard 
Figure A 30 Characterization of peak ‘e’ by 1H-NMR spectroscopy 
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Synthetic standard 
Peak h 
Figure A 31 Characterization of peak ‘h’ by 1H-NMR spectroscopy 
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Synthetic standard 
Peak d 
Peak h 
Figure A 32 Comparison of 1H-NMR spectra of peak‘d’ and peak ‘h’ 
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Peak f 
Peak b 
Standard 
Figure A 33 Characterization of peaks ‘b’ and ‘f’ by 1H-NMR spectroscopy 
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Peak f 
Peak b 
Standard 
Figure A 34 Characterization of peaks ‘b’ and ‘f’ by 13C-NMR spectroscopy 
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Peak b 
Peak f 
Standard 
Figure A 35 Characterization of peaks ‘b’ and ‘f’ by HSQC correlation 
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Peak b 
Peak f 
Standard 
Figure A 36 Characterization of peaks ‘b’ and ‘f’ by COSY correlation 
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Peak b 
Peak f 
Standard 
Figure A 37 Characterization of peaks ‘b’ and ‘f’ by low energy HMBC correlation 
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Peak b 
Peak f 
Standard 
Figure A 38 Characterization of peaks ‘b’ and ‘f’ by high energy HMBC correlation 
